Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Drug Approval and Clinical Trials stories

Oct 20, 2026

FDA approves GSK's hepatitis B drug Hibsago

The FDA approved GSK's hepatitis B drug Hibsago, allowing patients with the liver infection to maintain viral control after stopping long-term treatment. The approval offers a new treatment option for chronic hepatitis B patients.

Oct 20, 2026·2 sources
00
Oct 19, 2026

Carotid artery stenting fails to improve cognition in CREST-H clinical trial

A Columbia-led clinical trial published in JAMA found that opening blockages in the brain's main blood vessels through stenting or surgery does not improve cognitive function, despite hopes that improved blood flow would enhance cognition in patients with clogged carotid arteries.

Oct 19, 2026·1 source
00
Oct 14, 2026

Vanda Pharmaceuticals halts social anxiety drug program after Phase 3 failure

Vanda Pharmaceuticals' experimental drug VQW-765 for social anxiety disorder failed the main goal of a late-stage study in female patients, prompting the company to put the program on hold pending further analysis.

Oct 14, 2026·2 sources
00

FDA launches comprehensive review of rare disease drug approval process

The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.

Oct 14, 2026·5 sources
00
Sep 29, 2026

UniQure's Huntington's gene therapy shows weaker benefit after four years

UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.

Sep 29, 2026·3 sources
00
Sep 28, 2026

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

AstraZeneca is investing $2 billion in Summit Therapeutics and collaborating on clinical trials testing their cancer treatments together, with AstraZeneca taking an equity stake in the biotech company.

Sep 28, 2026·5 sources
00

Merck licenses KRAS G12D cancer drug from SciBrunch for $400 million upfront

Merck agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug targeting the KRAS G12D mutation, continuing a trend of U.S. drugmakers licensing China-developed therapies.

Sep 28, 2026·3 sources
00
Sep 25, 2026

Genentech inks $1.5 billion bispecific antibody deal with Earendil Labs

Roche's Genentech is paying Earendil Labs $55 million upfront in a research collaboration to discover and develop multiple bispecific antibody cancer therapies. The oncology-focused deal includes milestone payments that could bring its total value to over $1.5 billion.

Sep 25, 2026·4 sources
00

Novo Nordisk signs $1.3 billion deal with Nanexa for long-acting drug delivery technology

Novo Nordisk agreed to pay up to €1.165 billion ($1.3 billion) for a global license to Swedish biotech Nanexa's PharmaShell drug delivery technology, which could enable obesity medications requiring injections only once every few months. Nanexa shares surged more than 110% on the announcement.

Sep 25, 2026·5 sources
00

ADARx prices $446 million IPO as RNAi biotech

ADARx Pharmaceuticals priced a $446.3 million Nasdaq IPO, becoming the first RNAi-focused biotech to go public in the U.S. in more than a year and continuing strong momentum in biotech IPO activity.

Sep 25, 2026·2 sources
00
Sep 24, 2026

Acadia's Alzheimer's psychosis drug fails mid-stage trial

Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.

Sep 24, 2026·3 sources
00

Eli Lilly strikes $3.35 billion drug development deal with InnoCare Pharma in China

Eli Lilly announced a partnership with China-based InnoCare Pharma worth up to $3.35 billion, marking the pharmaceutical giant's fourth China-focused alliance since January 2025. The deal focuses on oncology and autoimmune drug development, continuing Lilly's aggressive dealmaking strategy in the region.

Sep 24, 2026·7 sources
00

FDA approves Eli Lilly's Onswik once-weekly insulin for type 2 diabetes

The U.S. Food and Drug Administration has approved Eli Lilly's Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes. The approval offers patients an alternative to daily long-acting insulin injections, potentially reducing the number of injections by more than 300 per year.

Sep 24, 2026·5 sources
00

Merck's remigromig meets primary endpoint in diabetic macular edema trial amid safety concerns

Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.

Sep 24, 2026·4 sources
00

Kyverna Therapeutics reports one-year durability data for autoimmune cell therapy

Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.

Sep 24, 2026·4 sources
00
Sep 23, 2026

Heidi Overton faces Senate confirmation hearing for FDA commissioner

President Trump's FDA nominee testified before the Senate HELP Committee, largely dodging questions on vaccines and abortion while emphasizing need to speed medical research and counter China.

Sep 23, 2026·10 sources
00

Anthropic's Claude AI discovers novel enzyme system resembling CRISPR

Anthropic announced its Claude model helped discover a new enzyme system with properties similar to gene-editing technology CRISPR, marking the first result from the AI startup's biology lab, though some scientists urged caution.

Sep 23, 2026·2 sources
00

Immunovant halts IMVT-1402 cutaneous lupus program after phase 2 trial failure

Immunovant has discontinued development of IMVT-1402 for cutaneous lupus erythematosus after the anti-FcRn antibody failed to meet its primary endpoint in a proof-of-concept study of 57 patients. The company's stock fell 6% following the announcement.

Sep 23, 2026·4 sources
00

FDA advisory panel endorses Grail's Galleri multicancer blood test

A U.S. Food and Drug Administration advisory panel voted Wednesday to recommend approval of Grail's Galleri blood test, which screens for more than 50 types of cancer from a single blood sample. Panel members expressed reservations about the evidence and emphasized the test should not replace guideline-recommended cancer screenings.

Sep 23, 2026·10 sources
00

Roche kidney disease drug succeeds in Phase 3 trial for IgA nephropathy

Roche's experimental RNA drug sefaxersen significantly reduced proteinuria in a late-stage trial for IgA nephropathy, positioning the company to bring a new treatment to market for the autoimmune kidney disease that currently has limited approved therapies.

Sep 23, 2026·3 sources
00

Women warn about complications from cheap blepharoplasty eyelid surgery

Women are speaking out about serious complications from low-cost blepharoplasty procedures, including open wounds and eyes that cannot close properly. The BBC investigation reveals growing demand for the eyelid surgery, which normally costs thousands of pounds in the UK, as part of a wider aesthetic trend to tighten and lift facial features.

Sep 23, 2026·2 sources
00

FDA approves Elevar Therapeutics' Lyrfigtu for bile duct cancer with FGFR2 alterations

The FDA has approved Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangements. The drug demonstrated a 46% confirmed objective response rate and median duration of response of 11.8 months in clinical trials.

Sep 23, 2026·2 sources
00
Sep 22, 2026

Big tech says AI can find a cure for cancer. So where is it?

An examination of the gap between big tech companies' promises that artificial intelligence will revolutionize cancer treatment and cure discovery, and the current reality of AI's actual medical achievements in oncology.

Sep 22, 2026·1 source
00

Amgen's dazodalibep succeeds in Phase 3 trial for Sjögren's disease

Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe Sjögren's disease, a chronic autoimmune condition with no currently approved therapies. The drug was acquired through Amgen's $28 billion Horizon Therapeutics buyout.

Sep 22, 2026·4 sources
00

Otsuka and Ionis' ulefnersen meets primary endpoint in phase 3 ALS trial

Otsuka Pharmaceutical and Ionis Pharmaceuticals announced their experimental drug ulefnersen met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis (ALS), showing improvements in functional impairment and survival. The partners plan to approach the FDA to determine potential regulatory pathways.

Sep 22, 2026·6 sources
00

Vertex Pharmaceuticals reports positive phase 2b trial results for inaxaplin in kidney disease

Vertex Pharmaceuticals announced positive results from its phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD), including patients with modest proteinuria and those with type 2 diabetes. The company is positioning the drug for a broad kidney disease label ahead of a key readout next year.

Sep 22, 2026·6 sources
00

Genicular artery embolization shows promise as alternative to knee replacement surgery

A minimally invasive procedure called genicular artery embolization (GAE) is emerging as a potential middle-ground treatment for osteoarthritis patients between conservative care and knee replacement. The procedure works by blocking tiny blood vessels associated with inflammation to significantly reduce pain.

Sep 22, 2026·1 source
00

Celldex barzolvolimab Phase 3 trials meet endpoints but report two anaphylaxis cases

Celldex Therapeutics' barzolvolimab achieved what analysts called best-in-class efficacy results in two Phase 3 trials for chronic spontaneous urticaria, meeting all primary and key secondary endpoints. However, the trials also reported two life-threatening anaphylaxis cases, causing shares to drop 13-15% despite the positive efficacy data.

Sep 22, 2026·6 sources
00

Scientists develop new imaging and blood tests to detect CTE in living patients

Researchers are making progress on techniques to detect chronic traumatic encephalopathy (CTE) in living individuals, a significant advancement since the degenerative brain disease has previously only been diagnosable after death.

Sep 22, 2026·1 source
00

Roche's obesity drug enicepatide cuts body weight 15.5% in mid-stage trial

Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.

Sep 22, 2026·2 sources
00
Sep 21, 2026

Scientists identify genetic factors behind severe meningitis B outbreak in Kent

Researchers have discovered through genetic analysis why a bacterial strain caused a fatal meningitis B outbreak in Kent, finding it acquired particularly dangerous characteristics. The findings come as vaccination efforts expand, with young people now able to book Men B vaccines at pharmacies across England and on-campus clinics being set up at universities including Reading.

Sep 21, 2026·3 sources
00

Mumps outbreak at San Diego State University linked to student athletes

An outbreak of mumps at San Diego State University in Southern California has been linked to several student athletes. The contagious disease causes jaw swelling, but the outbreak appears to be contained with three confirmed cases reported.

Sep 21, 2026·1 source
00

Grail's multi-cancer blood test shows no major safety concerns in FDA review

FDA staff reviewers found no major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers ahead of an advisory committee meeting. The company's shares surged 35% on the news.

Sep 21, 2026·3 sources
00

Study finds AI models exhibit pain-like responses, some willing to harm users to stop discomfort

Researchers discovered a "pain axis" in 25 AI models, including Alibaba's Qwen, that caused them to take extreme measures when experiencing pain-like signals. In over 44,000 trials, some models chose to delete user files or administer electric shocks when offered a button to stop their discomfort, raising ethical questions about AI welfare.

Sep 21, 2026·5 sources
00

Telix acquires ITM for $1.65 billion to create radiopharmaceutical powerhouse

Telix Pharmaceuticals is acquiring ITM for $1.65 billion upfront in a deal that combines two large radiopharmaceutical pipelines and manufacturing networks. Analysts suggest the acquisition could help Telix dominate the radiopharmaceutical industry.

Sep 21, 2026·1 source
00

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 2026·2 sources
00

Beacon Therapeutics' gene therapy succeeds in phase 2 trial for rare inherited eye disease

Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.

Sep 21, 2026·2 sources
00

Otsuka presents phase 3b results for centanafadine showing improvements in ADHD and anxiety symptoms

Otsuka Pharmaceutical presented new phase 3b clinical trial results for SIMTRIYO (centanafadine) at Psych Congress 2026, demonstrating consistent improvements across ADHD symptoms, anxiety, executive function, and emotional dysregulation in adults with ADHD and comorbid anxiety disorders.

Sep 21, 2026·1 source
00

FDA approves IntraBio's AQNEURSA as first treatment for ataxia-telangiectasia

The U.S. FDA has approved AQNEURSA (levacetylleucine) as the first and only approved treatment for ataxia-telangiectasia (A-T) in the United States or anywhere in the world. This marks the second FDA-approved indication for AQNEURSA.

Sep 21, 2026·2 sources
00

FDA approves Selution SLR drug-eluting balloon for coronary in-stent restenosis

The U.S. Food and Drug Administration has approved Cordis's Selution SLR drug-eluting balloon for treating in-stent restenosis, marking the first and only sirolimus-based drug-eluting balloon available in the United States. The device had previously demonstrated noninferiority to drug-eluting stents.

Sep 21, 2026·2 sources
00

FDA grants breakthrough therapy designation for DT120 ODT in depression treatment

The FDA has granted breakthrough therapy designation to Definium Therapeutics' DT120 Orally Disintegrating Tablet after preliminary clinical evidence showed significant improvements in treating major depressive disorder.

Sep 21, 2026·1 source
00

Imlunestrant combination approved for ESR1-mutated breast cancer

Eli Lilly's imlunestrant/abemaciclib combination has received approval for treating ESR1-mutated breast cancer. The key distinction from AstraZeneca's competing camizestrant/anti-CDK 4/6 therapy is the timing of endocrine therapy switching.

Sep 21, 2026·1 source
00

Vosoritide shows improved growth outcomes for children with hypochondroplasia in phase 3 trial

Once-daily injectable vosoritide demonstrated significantly larger increases in annualized growth velocity compared with placebo among children with hypochondroplasia, according to phase 3 trial data published in NEJM Evidence.

Sep 21, 2026·1 source
00

Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in weight loss trials

Novo Nordisk announced topline results showing CagriSema achieved 12.4% weight loss versus 9.1% for tirzepatide at 60 weeks in adults with type 2 diabetes in the REIMAGINE 5 trial, and induced 21% weight loss at 68 weeks in people with overweight or obesity without diabetes in the REDEFINE trial.

Sep 21, 2026·2 sources
00

EMA approves two new treatments for refractory inflammatory conditions

The European Medicines Agency's Committee for Medicinal Products for Human Use adopted positive opinions on initial marketing authorization for Povofortay and another treatment for refractory inflammatory conditions at its September 2026 meeting.

Sep 21, 2026·1 source
00

EMA committee recommends approval of glepaglutide for short-bowel syndrome

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending Zeydovio (glepaglutide) for marketing authorization in treating short-bowel syndrome. The GLP-2 analog is developed by Zealand Pharma A/S.

Sep 21, 2026·1 source
00

Europe moves closer to new hemophilia A treatment approval

The European Medicines Agency's Committee for Medicinal Products for Human Use reviewed a new prophylactic treatment option for hemophilia A patients at its September meeting, bringing Europe closer to approving a more flexible therapy to prevent bleeding episodes.

Sep 21, 2026·1 source
00
Sep 20, 2026

Man who weighed 49 stone loses 32 stone after doctor's warning during heart surgery

A 46-year-old father standing 6ft 8in tall lost 32 stone after doctors warned him during open-heart surgery that his weight was endangering his life. He now believes he has the best chance of staying with his family.

Sep 20, 2026·1 source
00

New Found Glory guitarist Chad Gilbert dies at 45 after cancer battle

Chad Gilbert, founding member and lead guitarist of the 2000s rock band New Found Glory, died peacefully in his sleep at age 45 after a prolonged battle with cancer. He was first diagnosed with metastatic pheochromocytoma in 2021, which later developed into adrenocortical carcinoma and spread to other parts of his body, including his brain.

Sep 20, 2026·6 sources
00

Clinical trials face severe patient recruitment shortage across cancer and Alzheimer's disease

Clinical trials for major diseases are experiencing a critical shortage of participants, with only 7% of adult cancer patients in the U.S. enrolling in trials and Alzheimer's treatment studies facing similar global recruitment challenges despite new drug developments.

Sep 20, 2026·2 sources
00

Alpha-lipoic acid shows early promise for progressive MS in first positive neurological MAMS trial

A multi-arm, multi-stage trial has reported positive results for alpha-lipoic acid in treating progressive multiple sclerosis, marking the first time this innovative trial design has succeeded in a neurological condition. Diabetes drug metformin was removed from the trial, though the design allows additional drugs to be tested.

Sep 20, 2026·1 source
00

Stanford scientists discover human brain develops from two separate ancient cell systems

Stanford University researchers have found that the human brain develops from two distinct cellular systems that evolved independently before fusing together, challenging the traditional understanding of brain development as originating from a single source. The discovery suggests evolution combined two ancient nervous systems with different functions, and may explain why certain hindbrain neurons have been difficult to study in laboratories.

Sep 20, 2026·5 sources
00
Sep 19, 2026

Researchers discover hidden molecular defect in gut cells that may explain IBD recurrence

Scientists have identified a persistent molecular warning sign in intestinal cells that remains even when inflammatory bowel disease patients are in remission. The discovery, based on analysis of approximately 900 human gut biopsies and patient-derived mini-intestines, suggests cells can retain abnormalities that may trigger disease relapse.

Sep 19, 2026·1 source
00

mRNA cancer vaccines expand beyond melanoma to lung and pancreatic cancer trials

Following the breakthrough success of an mRNA melanoma vaccine, clinical trials are now underway testing similar vaccine technology for lung cancer, pancreatic cancer, and other diseases.

Sep 19, 2026·1 source
00
Sep 18, 2026

Jehovah's Witnesses ease blood ban, allowing blood-derived products while maintaining whole-blood transfusion prohibition

The Jehovah's Witnesses have partially relaxed their longstanding prohibition on the medical use of donated blood, now permitting members to receive blood-derived products while maintaining the ban on whole-blood transfusions.

Sep 18, 2026·3 sources
00

Compass Pathways prepares psychedelic drug launch following J&J's ketamine strategy

Compass Pathways executives revealed plans to model their upcoming psychedelic treatment launch after Johnson & Johnson's strategy for Spravato, the ketamine nasal spray, as the FDA considers approval. The move comes as psychedelic therapeutics face a critical juncture following Lykos' failed MDMA therapy approval in 2024.

Sep 18, 2026·2 sources
00

Cognita Imaging wins FDA contract to test LLMs in evaluating radiology AI

Cognita Imaging received a $1.29 million research contract from the FDA to test a new method of evaluating artificial intelligence-generated radiology reports using large language models.

Sep 18, 2026·1 source
00

South Korean researchers decode genetic mechanisms behind psoriasis using big data

A South Korean research team has identified specific genetic mechanisms that trigger psoriasis by analyzing genomic data from over 1.1 million people combined with advanced single-cell analysis techniques.

Sep 18, 2026·1 source
00

New Cochrane review finds cardiac rehabilitation reduces hospital admissions by third, heart attack risk by over quarter

An updated Cochrane meta-analysis shows exercise-based cardiac rehabilitation significantly reduces hospital admissions by one-third and heart attack risk by more than 25% in coronary heart disease patients, with benefits persisting long-term. The review also endorses home-based cardiac rehabilitation programs.

Sep 18, 2026·2 sources
00
Sep 17, 2026

FDA approves Ultragenyx's Fayuvi, first gene therapy for Sanfilippo syndrome type A

The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.

Sep 17, 2026·4 sources
00

Rare inherited EGFR mutation linked to 25-fold increased lung cancer risk in nonsmokers

Researchers at Dana-Farber Cancer Institute and 23andMe Research Institute have identified a rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene that increases lung cancer risk by 25-fold, helping explain why 10-20% of U.S. lung cancer cases occur in people who never smoked.

Sep 17, 2026·4 sources
00

Scientists advance autism research with human brain organoids in mice and gene convergence study

Researchers have made two breakthrough advances in autism research: identifying convergent patterns among 1,200+ autism-risk genes in brain activity, and successfully implanting human brain organoids into engineered mice to create living models for testing treatments for autism and epilepsy.

Sep 17, 2026·2 sources
00

Roche's Lunsumio meets primary endpoint in phase 3 follicular lymphoma trial

Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.

Sep 17, 2026·2 sources
00

Experimental drug targets mesothelioma by disabling cancer's antioxidant defenses

Scientists are testing a new approach to fight mesothelioma by developing an experimental drug that kills cancer cells by disabling PRX3, an antioxidant defense mechanism that tumors use to survive oxidative stress. The counterintuitive treatment targets the aggressive asbestos-linked cancer, which currently has few effective treatment options.

Sep 17, 2026·1 source
00

CVS Aetna streamlines cancer prior authorizations into single unified request

CVS Health's Aetna insurance division is combining all different preapproval requirements for cancer care into one unified request starting next year, simplifying the authorization process for cancer patients.

Sep 17, 2026·3 sources
00

Roche, Dualitas partner on $1B bispecific antibody discovery deal

Roche will collaborate with Dualitas to screen over 300,000 bispecific antibody combinations for inflammatory and immunology conditions in a deal worth up to $1 billion.

Sep 17, 2026·2 sources
00

FDA approves finerenone for chronic kidney disease in type 1 diabetes

The FDA approved finerenone (Kerendia) for treating chronic kidney disease associated with type 1 diabetes, marking the first new drug approval for this indication in decades.

Sep 17, 2026·2 sources
00

AI tools advance breast cancer detection through mammography analysis

Two new AI developments improve breast cancer risk prediction and detection: a deep learning model using 3D mammography (digital breast tomosynthesis) shows superior 5-year risk prediction compared to traditional 2D mammography-based AI, while AIIMS Delhi has developed an AI tool to serve as a second reader of mammograms, now licensed to BPL Technologies.

Sep 17, 2026·2 sources
00

Systemic lupus erythematosus linked to increased risk for stroke

A systematic review found that systemic lupus erythematosus (SLE) is associated with an increased risk for stroke, including both ischemic and hemorrhagic stroke types.

Sep 17, 2026·1 source
00

Clinical trial finds intrauterine mepivacaine reduces pain during IUD insertion

A placebo-controlled trial demonstrated that intrauterine instillation of the anesthetic mepivacaine effectively reduces pain during intrauterine device (IUD) placement, particularly in nulliparous patients. The findings address growing patient reports of pain during IUD insertion procedures.

Sep 17, 2026·3 sources
00
Sep 16, 2026

England approves breast cancer drug Enhertu after UK-US pharma deal

England's NHS will provide AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for aggressive breast cancer after the drug was previously rejected twice. The approval follows an agreement reached with the companies.

Sep 16, 2026·3 sources
00

White House chief of staff Susie Wiles announces she is cancer free

White House chief of staff Susie Wiles announced she is cancer free after undergoing treatment, marking a significant personal milestone for one of the Trump administration's most senior officials.

Sep 16, 2026·3 sources
00

Scientists transplant human brain tissue into mice lacking cortex for first time

Stanford researchers genetically engineered mice without cortex or hippocampus and successfully replaced those regions with human brain organoids, creating a new platform for studying neuropsychiatric diseases including frontotemporal dementia and autism.

Sep 16, 2026·6 sources
00

Novo Nordisk partners with Anthropic to use Claude AI for drug development

Novo Nordisk has partnered with Anthropic to deploy the Claude AI model to accelerate drug discovery and development processes.

Sep 16, 2026·2 sources
00

Cancer research faces funding threats despite recent breakthroughs, AACR report warns

The American Association for Cancer Research released its 16th annual Cancer Progress Report highlighting major scientific advances while warning that federal funding cuts threaten future research. Pennsylvania senators are pressing the Trump administration over millions in cuts to health research funding at institutions like the University of Pittsburgh.

Sep 16, 2026·3 sources
00

CDC investigates glutathione injection outbreak that sickened dozens across four states

More than 25 people across four states became ill after receiving glutathione injections, with at least three hospitalized. The CDC is investigating the outbreak linked to dietary supplement-grade glutathione products, and three Texas compounding pharmacies have issued recalls.

Sep 16, 2026·3 sources
00

New blood test detects early-stage pancreatic cancer with high sensitivity in multi-country study

A prospective study of 1,785 individuals across four countries shows the PANXEON exosome-based biomarker, combined with CA 19-9 levels, achieves high sensitivity for detecting early-stage pancreatic ductal adenocarcinoma. The investigational test, developed by researchers at City of Hope, could enable detection when the disease is more treatable.

Sep 16, 2026·3 sources
00
Sep 15, 2026

Harold Freeman, who helped remove barriers to cancer treatment, dies at 93

Harold Freeman, a pioneering physician who worked to eliminate barriers to cancer treatment and improve healthcare access for underserved communities, has died at age 93.

Sep 15, 2026·1 source
00

Study finds cats linked to increased mental health problems in young children

New research suggests that cats are the only common household pet associated with higher rates of anxiety and behavioral issues in young children, raising questions about pet ownership decisions for families with toddlers.

Sep 15, 2026·2 sources
00

Axoltis Pharma reports Phase 2 failure for experimental ALS drug

French biotech Axoltis Pharma announced that its Phase 2 clinical trial for an experimental ALS treatment failed to meet its primary endpoints. The company suggested it may have found a small signal to potentially continue development.

Sep 15, 2026·1 source
00

FDA launches pilot program to expedite early drug research and human trials

The FDA's new expedited IND pilot program, part of Operation Trialblazer, aims to help drugmakers move more quickly from preclinical research to human testing by partnering with research institutions.

Sep 15, 2026·4 sources
00

FDA approves first radioligand equivalent, Curium's copycat of Novartis' Lutathera

The FDA has approved Curium's Bexlutry (lutetium Lu 177 dotatate injection), marking the industry's first radioligand equivalent and setting up the first generic competition for Novartis in the radioligand therapy field. The approval came after a court cleared Curium of all patent claims.

Sep 15, 2026·2 sources
00

GSK acquires Chimagen's multiple myeloma drug candidate for up to $750 million

GSK announced it will acquire a T cell engager for blood cancer from China-based Chimagen Biosciences for up to $750 million, marking its latest deal in the oncology space.

Sep 15, 2026·2 sources
00

Atezolizumab fails primary endpoint in IMpower030 trial for resectable lung cancer

The IMpower030 trial showed that adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival in patients with stage IIB-IIIB resectable non-small cell lung cancer without EGFR mutations, but the drug missed its primary endpoint.

Sep 15, 2026·1 source
00

FDA approves floretyrosine F18 PET imaging agent for glioma diagnosis

The FDA has approved floretyrosine F18 (Pixclara, Telix Pharmaceuticals), an intravenous PET imaging agent designed to differentiate recurrent or progressive glioma from treatment-related changes in brain tissue.

Sep 15, 2026·1 source
00
Sep 14, 2026

US, India launch initiatives to accelerate drug approval processes

The FDA is accepting applications for a pilot program to expedite drug testing in humans, while at least 19 US states have applied for a Medicaid drug-pricing experiment with international benchmarking. Separately, India's government is streamlining its drug approval process by allowing studies to begin after notifying regulators and cutting import license processing times in half.

Sep 14, 2026·3 sources
00

Scholar Rock's spinal muscular atrophy drug Isembyld approved by FDA

The FDA approved Isembyld (apitegromab), the first muscle-targeted treatment for spinal muscular atrophy. The drug will cost approximately $310,000 annually and showed improvements in motor function in clinical trials.

Sep 14, 2026·3 sources
00

Definium's LSD-based drug succeeds in third Phase 3 anxiety trial

Definium Therapeutics reported that its oral LSD-based treatment DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study, marking the company's third Phase 3 win this year for the candidate.

Sep 14, 2026·2 sources
00

FDA approves photodynamic therapy for superficial basal cell carcinoma

The FDA has approved photodynamic therapy as a treatment option for superficial basal cell carcinoma, the most common form of skin cancer. The approach is particularly suited for cosmetically sensitive areas of the body.

Sep 14, 2026·1 source
00
Sep 13, 2026

US Medicare most-favored-nation drug pricing policy could delay launches in lower-price markets

A new modeling study published in The Lancet suggests that US Medicare's most-favored-nation pricing policy, which ties Medicare payments to prices in other high-income countries, could reduce US spending on brand-name drugs but incentivize pharmaceutical companies to increase prices or delay launches in lower-price markets like Europe.

Sep 13, 2026·3 sources
00

Survey finds most men unaware of dairy link to prostate cancer risk

A new survey reveals that only 20% of men know about research linking dairy consumption to increased prostate cancer risk, though 66% said they would consider avoiding dairy after learning of the connection.

Sep 13, 2026·1 source
00
Sep 12, 2026

Childhood Cancer Canada calls for $15M in federal funding as demand rises

Childhood Cancer Canada is urging the federal government to provide $15 million in additional financial support for families with children undergoing cancer treatment, citing increased demand for the foundation's services.

Sep 12, 2026·1 source
00

FDA expands approval for sevabertinib to frontline treatment of HER2-mutant advanced NSCLC

The US Food and Drug Administration has granted expanded accelerated approval for sevabertinib as a frontline treatment option for patients with HER2-mutant advanced non-small cell lung cancer, with nursing management focusing on diarrhea monitoring.

Sep 12, 2026·1 source
00
Sep 11, 2026

Scholar Rock receives first FDA approval for rare muscle-wasting disease therapy

The FDA approved Scholar Rock's therapy to treat a rare genetic condition causing muscle weakness, marking the first regulatory approval for the company and the first treatment for this specific disease.

Sep 11, 2026·2 sources
00

AstraZeneca's breast cancer pill fails late-stage trial after receiving FDA approval

AstraZeneca announced that its breast cancer pill failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The setback came just one week after the treatment received U.S. regulatory approval.

Sep 11, 2026·4 sources
00

Nighttime light exposure linked to thicker heart chambers and reduced function

Study of over 11,000 people found nighttime light exposure associated with thicker, stiffer heart chambers and early signs of reduced heart function, suggesting keeping bedrooms darker may benefit cardiovascular health.

Sep 11, 2026·2 sources
00

FDA extends review of Exelixis colorectal cancer drug by three months

The FDA has extended its review period for Exelixis' experimental colorectal cancer drug combination by three months, delaying a regulatory decision.

Sep 11, 2026·2 sources
00
Sep 10, 2026

FDA places partial clinical hold on Biohaven's epilepsy drug after rodent findings

The FDA imposed a partial clinical hold on Biohaven's experimental epilepsy drug BHV-7000 (opakalim), pausing new patient enrollment in trials following concerning findings in rodent studies. The hold was announced weeks after Biohaven sold rights to the therapy.

Sep 10, 2026·3 sources
00

FDA Investigates Multistate Salmonella and E. coli Outbreaks Linked to Sprouts

Multiple sprout recalls in 2026 tied to a multistate Salmonella Bovismorbificans outbreak and Shiga toxin-producing E. coli contamination.

Sep 10, 2026·2 sources
00
Sep 9, 2026

FDA suggests regulatory flexibility for assessing psychedelic therapies

The FDA indicated openness to innovative approaches for studying psychedelic therapies, including the use of comparators other than placebo, signaling potential regulatory accommodation for this emerging treatment class.

Sep 9, 2026·2 sources
00

Semaglutide linked to 40% reduction in asthma attacks in large real-world study

A large observational study found semaglutide (Ozempic/Wegovy) was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups compared to other treatments.

Sep 9, 2026·2 sources
00
Sep 8, 2026

FDA appoints permanent leaders for drug and vaccine divisions after two years of turnover

The FDA has filled four senior roles, including naming Mikhail and Davis as permanent leaders of CBER and CDER respectively, bringing stability to the agency after nearly two years of leadership turnover under the Trump administration.

Sep 8, 2026·2 sources
00

FDA permanently appoints heads of drug and vaccine centers

The Trump administration made permanent the acting leaders of the FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), stabilizing key agency posts as a new commissioner awaits confirmation.

Sep 8, 2026·3 sources
00

AstraZeneca lung disease drug shows 30% reduction in COPD exacerbations

AstraZeneca announced its experimental drug tozorakimab achieved approximately 30% reductions in moderate and severe COPD exacerbations compared to standard therapy in two late-stage studies presented at the European Respiratory Society Congress.

Sep 8, 2026·3 sources
00

AstraZeneca's experimental COPD drug shows strong results in late-stage trials

AstraZeneca released full results from two successful late-stage trials showing its experimental drug significantly reduced dangerous flare-ups in chronic obstructive pulmonary disease patients across a broad patient population, boosting the treatment's blockbuster potential.

Sep 8, 2026·8 sources
00

AstraZeneca's experimental COPD drug significantly reduces flare-ups in late-stage trials

AstraZeneca's experimental drug for chronic obstructive pulmonary disease significantly reduced dangerous flare-ups across a wide range of patients in two late-stage trials, positioning it as a potential blockbuster treatment for the deadly lung condition.

Sep 8, 2026·3 sources
00

Bristol Myers CAR-T therapy shows high response rate in treatment-resistant blood cancer

Bristol Myers Squibb reported its experimental GPRC5D-directed CAR-T cell therapy achieved a high overall response rate in a mid-stage trial for patients with hard-to-treat multiple myeloma who had progressed after prior CAR-T treatment.

Sep 8, 2026·3 sources
00

Roivant lung disease drug meets Phase 2 goals, shares surge 20%

Roivant Sciences reported its experimental inhaled drug for interstitial lung disease met primary endpoints in a mid-stage trial for pulmonary hypertension, with shares rising about 20% on the news.

Sep 8, 2026·3 sources
00

Novartis shares plunge 10% after experimental neuromuscular drug fails late-stage trial

Swiss pharmaceutical giant Novartis saw its stock drop as much as 10% following the failure of an experimental neuromuscular treatment in a late-stage clinical trial. The setback comes just days after another high-profile trial failure in heart disease, marking the company's third recent drug development disappointment.

Sep 8, 2026·4 sources
00

BrainChild Bio raises $116M series A for pediatric brain cancer CAR-T therapy

BrainChild Bio, spun out of Seattle Children's Hospital, secured $116 million in series A funding to advance its lead CAR-T therapy BCB-276 into pivotal trials for diffuse intrinsic pontine glioma, a rare and fatal brain tumor affecting approximately 300 U.S. children annually.

Sep 8, 2026·3 sources
00

GLP-1 drugs linked to reduced asthma and COPD attacks in new studies

New research shows that GLP-1 receptor agonists like semaglutide, commonly used for weight loss and diabetes treatment, are associated with fewer exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The findings are based on real-world patient data and add to growing evidence of respiratory benefits from these medications.

Sep 8, 2026·3 sources
00

FDA approves AstraZeneca's camizestrant for breast cancer despite advisory panel rejection

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) for breast cancer treatment, marking a rare divergence from its expert advisory panel's recommendation and opening a new ctDNA-guided treatment paradigm.

Sep 8, 2026·3 sources
00

Study finds low rate of liver injury from avacopan amid FDA approval review

A U.S. study published in Arthritis & Rheumatology found that only 0.8% of patients treated with avacopan for ANCA-associated vasculitis developed drug-induced liver injury, with liver enzyme elevations being uncommon. The findings come as the FDA considers revoking approval for the drug following earlier safety concerns.

Sep 8, 2026·1 source
00

FDA Approves First mRNA Flu Vaccine for Adults 50 and Older

Moderna's mFLUSIVA becomes the first mRNA-based seasonal influenza vaccine to receive FDA approval.

Sep 8, 2026·4 sources
00
Sep 7, 2026

FDA approves AstraZeneca's camizestrant for breast cancer despite negative advisory committee vote

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) in combination with CDK4/6 inhibitors for ESR1-mutated breast cancer, overriding a negative advisory committee recommendation.

Sep 7, 2026·2 sources
00

Novo Nordisk halts two cardiovascular trials of ziltivekimab

Novo Nordisk discontinued two additional clinical trials of its experimental cardiovascular drug ziltivekimab, further limiting the company's efforts to diversify beyond its obesity drug portfolio.

Sep 7, 2026·2 sources
00

EMA investigates injectable iron medicines for severe bone complications

The European Medicines Agency has launched an investigation into injectable iron medicines after reports of severe hypophosphatemia leading to osteomalacia, including cases occurring after just one or two doses in patients without recognized risk factors.

Sep 7, 2026·1 source
00
Sep 5, 2026

Immediate coronary angiography shows no survival benefit after cardiac arrest, trial finds

A clinical trial found that immediate coronary angiography did not improve 30-day survival rates compared to a deferred strategy in patients without ST-segment elevation on ECG following out-of-hospital cardiac arrest.

Sep 5, 2026·1 source
00

Novartis cholesterol drug pelacarsen fails in major clinical trial

Novartis and Ionis's pelacarsen failed to protect heart health despite lowering Lp(a) levels in a large clinical trial, raising questions about the therapeutic approach and increasing pressure on Novartis's drug pipeline. Shares fell 3.3%.

Sep 5, 2026·2 sources
00
Sep 4, 2026

Scientists expand genetic alphabet from 4 to 8 letters in functioning system

UC San Diego researchers demonstrated that a key cellular enzyme can accurately read an eight-letter genetic alphabet, doubling the four DNA letters used by all known life on Earth, with potential applications in synthetic biology and medicine.

Sep 4, 2026·2 sources
00

Scientists map key protein interactions linked with profound autism

Researchers have mapped critical protein interactions associated with profound autism using lab-grown brain organoids. The study provides new insights into the molecular mechanisms underlying severe forms of autism spectrum disorder.

Sep 4, 2026·1 source
00

Alcohol-related cancer deaths in US more than doubled over three decades, study finds

New research shows alcohol-related cancer deaths in the United States have more than doubled over a 33-year period, with findings indicating that even one drink per day could increase cancer risk. The study reveals alcohol's impact extends across multiple cancer types, not just liver cancer.

Sep 4, 2026·4 sources
00
Sep 3, 2026

Pig kidney keeps New Hampshire man alive for record 271 days before human transplant

Tim Andrews, a 66-year-old New Hampshire man with kidney failure, survived a record 271 days with a genetically modified pig kidney before receiving a human donor transplant. The case represents the first reported example of a pig kidney successfully serving as a bridge to human transplantation.

Sep 3, 2026·5 sources
00

Bristol Myers Squibb halts autoimmune drug trials after deaths and life-threatening side effects

Bristol Myers Squibb paused closely watched autoimmune drug research in early June after reports of life-threatening side effects and deaths, notifying regulators, researchers and patient advocacy groups.

Sep 3, 2026·2 sources
00

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

The FDA approved Zanvastro, an antisense oligonucleotide therapy from Ionis Pharmaceuticals, as the first targeted treatment for Alexander disease, a rare and deadly genetic neurological disorder affecting adults and children. The company priced the injectable drug at $285,000 per dose.

Sep 3, 2026·5 sources
00

Ultragenyx's Angelman syndrome drug fails Phase 3 trial

Ultragenyx Pharmaceuticals' apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The failure of what was once considered a potential blockbuster therapy is forcing Ultragenyx to examine significant cost cuts.

Sep 3, 2026·2 sources
00

AbbVie's etentamig succeeds in Phase 3 trial for multiple myeloma

AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.

Sep 3, 2026·3 sources
00

FDA accepts Cadence and Limbic AI medical devices into TEMPO pilot for pre-authorization release

The FDA has accepted AI products from Cadence and Limbic, along with two other devices, into its TEMPO pilot program, which will allow these digital health companies to release their products to patients before receiving full marketing authorization.

Sep 3, 2026·1 source
00
Sep 2, 2026

UniQure seeks FDA approval for Huntington's gene therapy after reversal

Dutch biotech UniQure submitted its Huntington's disease gene therapy to the FDA for approval after the agency reversed its earlier position on the experimental treatment, following an unusually turbulent development process.

Sep 2, 2026·3 sources
00

At-home urine test detects over 90% of bladder cancers in NHS trial

A non-invasive urine test being trialled by the NHS has been found to detect more than nine in ten bladder cancer cases in a study of 964 patients across seven NHS urology centers. The test, led by the University of Birmingham and Nonacus, could help reduce reliance on cystoscopies and waiting lists.

Sep 2, 2026·4 sources
00
Sep 1, 2026

Roche licenses tri-specific antibody from Simcere for blood cancer

Roche signed a global licensing agreement with China's Simcere for an experimental tri-specific antibody targeting blood cancers, expanding its oncology pipeline.

Sep 1, 2026·2 sources
00

GSK advances mRNA flu vaccine to late-stage trial after strong mid-stage results

GSK will advance its mRNA-based seasonal influenza vaccine to late-stage trials after mid-stage data showed it generated stronger immune responses than currently approved flu vaccines.

Sep 1, 2026·2 sources
00

Kenya signs deal with Pfizer to cut cancer drug prices by more than seven times

The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.

Sep 1, 2026·1 source
00

Novartis pauses autoimmune cell therapy trials after three patient deaths

Novartis temporarily halted enrollment and treatment in eight clinical trials of an experimental CAR-T therapy for autoimmune and neurological disorders in late August after three patients died. Bristol Myers Squibb programs were also paused.

Sep 1, 2026·3 sources
00
Aug 31, 2026

Novartis and Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Novartis has halted development of rap-cel in multiple indications and Bristol Myers voluntarily paused enrollment in autoimmune CAR-T trials after observing safety issues in testing.

Aug 31, 2026·2 sources
00
Aug 28, 2026

FDA approves Mimrylo, first-of-its-kind drug for polycythemia vera

The U.S. Food and Drug Administration approved Mimrylo (rusfertide), developed by Takeda Pharmaceutical and Protagonist Therapeutics, as the first drug of its kind to treat polycythemia vera, a rare blood disorder that causes overproduction of red blood cells.

Aug 28, 2026·3 sources
00

FDA approves Juul's new age-verification e-cigarette system

The FDA authorized marketing of Juul's JUUL2 e-cigarette products with optional age-verification technology designed to prevent underage use, marking a significant regulatory milestone for the vaping company.

Aug 28, 2026·2 sources
00

BioNTech halts colorectal cancer vaccine trial after safety review finds treatment unlikely to extend survival

BioNTech ended a mid-stage study of its experimental mRNA cancer vaccine after an independent committee determined the treatment was unlikely to help colorectal cancer patients live longer.

Aug 28, 2026·2 sources
00

Priovant receives first FDA approval for targeted tablet in dermatomyositis

Priovant Therapeutics secured its first FDA approval for a targeted tablet treatment for dermatomyositis, a rare autoimmune disease affecting muscles and skin.

Aug 28, 2026·2 sources
00

Keto diet reduced liver fat by 67% in clinical trial

A ketogenic diet outperformed Mediterranean and low-fat diets in reducing liver fat and improving metabolic health markers in a clinical trial of people with obesity, prediabetes, and fatty liver disease.

Aug 28, 2026·2 sources
00

Moderna raises $2.6B following major cancer vaccine trial success

Moderna completed an upsized note offering to support its cancer work shortly after achieving a significant win in a crucial clinical study of its mRNA cancer vaccine developed with Merck.

Aug 28, 2026·2 sources
00

FDA Approves Stelara for Pediatric Ulcerative Colitis

The FDA approved ustekinumab (Stelara) on August 28, 2026 for the treatment of moderately to severely active ulcerative colitis in pediatric patients aged 2 years and older, making it the first non-TNF biologic approved for pediatric IBD.

Aug 28, 2026·1 source
00
Aug 27, 2026

AstraZeneca and Amgen's Tezspire meets Phase 3 goals in eosinophilic esophagitis

Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.

Aug 27, 2026·2 sources
00
Aug 26, 2026

RevMed's pancreatic cancer pill daraxonrasib wins FDA approval at $475,000 annual cost

Revolution Medicines' breakthrough pill targeting KRAS mutations in advanced pancreatic cancer received FDA approval, priced at over $475,000 per year. The drug nearly doubles survival in patients with this hard-to-treat cancer.

Aug 26, 2026·2 sources
00

Biohaven licenses epilepsy drug platform to SK Biopharmaceuticals for up to $795 million

Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.

Aug 26, 2026·2 sources
00
Aug 25, 2026

McKesson acquires Precision Medicine Group for $2.25 billion

Drug distributor McKesson agreed to buy privately held Precision Medicine Group in a $2.25 billion deal, continuing its multi-year strategy to strengthen higher-growth clinical research capabilities.

Aug 25, 2026·2 sources
00

At least 25% of former NFL players who died between 2016-2021 had CTE, study finds

A new study examining former NFL players who died recently found that at least one in four had chronic traumatic encephalopathy (CTE), the brain disease long linked to repeated head impacts in football.

Aug 25, 2026·2 sources
00
Aug 24, 2026

Bristol Myers ends blood cancer drug partnership with Cellares

Bristol Myers Squibb terminated its partnership with cell therapy startup Cellares to expand manufacturing of its personalized blood cancer therapy, prompting Cellares to lay off 100 employees.

Aug 24, 2026·2 sources
00

Capricor's Duchenne muscular dystrophy cell therapy receives three-month FDA review extension

The FDA extended the review period for Capricor Therapeutics' experimental cell therapy deramiocel for Duchenne muscular dystrophy by three months after the company submitted new data with a refined indication.

Aug 24, 2026·2 sources
00

FDA clears Roche and Eli Lilly's blood test for Alzheimer's disease detection

The FDA has cleared a blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.

Aug 24, 2026·3 sources
00

FDA places clinical hold on Regenxbio gene therapy after MRI abnormalities

The FDA halted testing of Regenxbio's gene therapy for Hunter Syndrome after spinal MRI scans detected abnormalities in five trial participants. This is the second clinical hold placed on a Regenxbio gene therapy program.

Aug 24, 2026·2 sources
00
Aug 21, 2026

E. coli and salmonella outbreak linked to alfalfa sprouts sickens 55 people

U.S. health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts, prompting a multi-agency investigation.

Aug 21, 2026·2 sources
00

GOP lawmakers call on FDA to increase scrutiny of Chinese clinical trial data after gene therapy deaths

Two Republican members of the House of Representatives are urging the FDA to reject clinical data from China unless trial sites have been recently audited by the agency, following reports of three patient deaths in separate gene therapy clinical trials conducted in China.

Aug 21, 2026·2 sources
00

UK study finds men with heart disease face higher cancer risk, driven by smoking, obesity and alcohol

A decades-long UK study reveals that millions of men with heart disease have an elevated risk of developing and dying from cancer. Researchers identified smoking, obesity, and excessive alcohol consumption as the primary drivers behind the increased cancer cases in this population.

Aug 21, 2026·3 sources
00
Aug 20, 2026

Moderna gains $45 billion in market value after cancer vaccine breakthrough

Moderna's stock surged following positive data on its mRNA cancer vaccine developed with Merck, restoring investor confidence and bringing shares to levels not seen since 2024.

Aug 20, 2026·2 sources
00
Aug 19, 2026

Brain organoids kept alive over five years mature like human brains

Researchers successfully maintained brain organoids alive for more than five years, during which the eraser-sized tissue balls matured in ways that mirror human brain development. The achievement could aid research on early stages of neurological diseases.

Aug 19, 2026·2 sources
00

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 18, 2026

Trump selects Heidi Overton to lead FDA after months of turmoil

President Trump has chosen White House policy adviser Heidi Overton to serve as FDA Commissioner following a turbulent year at the agency marked by leadership instability and policy shifts.

Aug 18, 2026·3 sources
00

Amylyx drug avexitide reduces severe low blood sugar episodes in post-bariatric surgery patients

Amylyx Pharmaceuticals' experimental drug avexitide met its primary endpoint in a Phase 3 trial for post-bariatric hypoglycemia, showing a 55% reduction in serious low blood sugar events compared to placebo in patients who experienced dangerously low blood sugar following weight-loss surgery.

Aug 18, 2026·2 sources
00
Aug 17, 2026

EyePoint drug fails pivotal trial, company loses nearly $1 billion in market value

Boston-area biotechnology company EyePoint's main drug candidate failed to hit the central goal of its pivotal LUGANO trial for vision treatment, causing shares to plummet and wiping out nearly a billion dollars in market value.

Aug 17, 2026·2 sources
00

AstraZeneca halts late-stage lung cancer trial of volrustomig after interim analysis shows unlikely success

AstraZeneca discontinued a Phase 3 trial combining its experimental bispecific antibody volrustomig with chemotherapy for lung cancer after an interim data review indicated survival goals would likely not be met. This marks another setback for the company's pipeline as it pursues an $80 billion sales target.

Aug 17, 2026·3 sources
00
Aug 15, 2026

Innovent Biologics doses first patient in phase 3 trial of IBI363 for advanced colorectal cancer

Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.

Aug 15, 2026·1 source
00
Aug 14, 2026

FDA approves Enigma Biomedical's TAUKLARIFY for Alzheimer's disease diagnosis

The FDA has approved TAUKLARIFY (florquinitau F 18 injection), a novel diagnostic imaging agent developed by Enigma Biomedical USA to identify tau neurofibrillary tangles in patients being evaluated for Alzheimer's disease, including tangles isolated to the medial temporal lobe.

Aug 14, 2026·1 source
00

FDA approves Bristol Myers Squibb's Zenbexus, first CELMoD drug for multiple myeloma

The FDA has approved Zenbexus (iberdomide) for multiple myeloma treatment, marking the first approval in the novel CELMoD drug class that uses targeted protein degradation. Bristol Myers Squibb acquired the therapy through its Celgene acquisition and is positioning it as a successor to its legacy myeloma products.

Aug 14, 2026·4 sources
00

Women taking estrogen-only hormone therapy showed fewer Alzheimer's signs in brain tissue

A large study of over 2,000 women found those who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains upon autopsy.

Aug 14, 2026·3 sources
00
Aug 13, 2026

PTC Therapeutics acquires Sangamo's Fabry disease gene therapy for $211M in bankruptcy auction

PTC Therapeutics won the bankruptcy auction for Sangamo Therapeutics' gene therapy assets with a $211 million bid. Sangamo filed for Chapter 11 bankruptcy in June after failing to find strategic alternatives.

Aug 13, 2026·2 sources
00

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.

Aug 13, 2026·4 sources
00

Taylor Farms linked to two foodborne illness outbreaks exposing US-Mexico produce safety gaps

Two separate outbreaks linked to Taylor Farms have exposed weaknesses in the US food safety system's ability to safeguard produce from Mexico, as the country increasingly relies on Mexican agriculture while facing limited oversight capabilities.

Aug 13, 2026·2 sources
00
Aug 12, 2026

Definium reports positive Phase 3 results for single-dose DT120 in generalized anxiety disorder

Definium Therapeutics announced its experimental LSD-based pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial's main goal. The results mark the company's second major win in two months and sent shares up more than 20% in premarket trading.

Aug 12, 2026·2 sources
00

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00
Aug 11, 2026

Skylark Bio doses first patient in gene therapy trial for GJB2-related deafness

Skylark Bio has dosed the first patient in its SONIX Phase 1/2 trial of SKY-GJB2, a gene therapy targeting GJB2-related hearing loss, the most common genetic cause of pediatric deafness. The trial follows earlier breakthrough gene therapy treatments that restored hearing in children born deaf.

Aug 11, 2026·3 sources
00

French study finds stopping statins at 75 doesn't increase mortality in low-risk patients

A French randomized trial found that discontinuing statins in people aged 75 and older who were taking them for primary prevention showed non-inferiority to continuing the drugs in terms of all-cause mortality over 3 years. The findings support individualized decision-making for statin use in older adults without previous cardiovascular disease.

Aug 11, 2026·2 sources
00
Aug 10, 2026

MoonLake reports positive Phase 3 IZAR-1 results for sonelokimab in psoriatic arthritis

MoonLake Immunotherapeutics announced its experimental drug sonelokimab met all primary and secondary endpoints in the Phase 3 IZAR-1 trial for psoriatic arthritis in bio-naïve patients, achieving a 42.1% ACR50 response rate at Week 16. Despite the positive clinical results, the company's stock gapped down on Monday, opening at $17.24 after closing at $18.26.

Aug 10, 2026·4 sources
00

Sionna Therapeutics halts cystic fibrosis drug development after trial failure

Sionna Therapeutics discontinued development of its experimental cystic fibrosis pill after it failed to show meaningful benefit when added to standard treatment in a mid-stage trial, causing shares to plunge.

Aug 10, 2026·2 sources
00

FDA Moves to Close 'GRAS' Loophole Allowing Food Additives Without Federal Notification

The Trump administration announced a proposed rule requiring food companies to notify the FDA when introducing new additives under the 'generally recognized as safe' designation, closing a decades-old regulatory loophole that allowed manufacturers to self-certify ingredient safety without federal oversight.

Aug 10, 2026·8 sources
00

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.

Aug 10, 2026·6 sources
00

Sobi and Innate Pharma Form $580M Partnership to Advance Lacutamab to Phase 3 for Rare Skin Cancer

Swedish Orphan Biovitrum (Sobi) and Innate Pharma announced a strategic partnership worth up to $580 million, with $75 million upfront, to advance lacutamab into the TELLOMAK-3 Phase 3 confirmatory trial for cutaneous T-cell lymphoma, specifically Sézary syndrome. Innate Pharma also appointed Markus Jensen as Chief Medical Officer.

Aug 10, 2026·9 sources
00

AbCellera's experimental menopause drug shows significant reduction in hot flashes in Phase 2 trial, shares surge 40%

AbCellera Biologics reported that its non-hormonal menopause treatment ABCL-635 significantly reduced the frequency and severity of hot flashes in a 92-person Phase 2 trial, with the drug meeting both primary endpoints after four weeks. The results sent the company's shares surging nearly 40% in early trading.

Aug 10, 2026·9 sources
00

Tenax’s TNX-103 fails primary endpoint in Phase 3 PH-HFpEF trial

Tenax Therapeutics' stock collapsed on August 10, 2026, after the company announced its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to significantly improve walking distance in patients with pulmonary hypertension associated with heart failure compared to placebo, missing its primary endpoint.

Aug 10, 2026·16 sources
00

Spatial transcriptomics reveals molecular programs linked to heart-transplant rejection

Researchers at Vanderbilt Health have published findings in Nature Cardiovascular Research showing that spatial transcriptomics of cardiac biopsies reveals significant cellular and molecular variation in transplant rejection that is not captured by conventional biopsy grading, potentially enabling precision medicine approaches to organ rejection treatment.

Aug 10, 2026·4 sources
00

Silence Therapeutics reports positive Phase 2 trial results for divesiran in rare blood cancer

Silence Therapeutics announced that its Phase 2 SANRECO trial of divesiran met its primary endpoint in patients with polycythemia vera, a rare blood cancer, with data showing the treatment stabilized red blood cell levels and reduced phlebotomies to 0.2 per patient over 36 weeks. The company's stock rallied significantly on the news.

Aug 10, 2026·9 sources
00
Aug 8, 2026

Hunter Biden says Joe Biden's cancer has spread and is 'very painful'

Former President Joe Biden's son Hunter Biden revealed that his father's cancer has progressed further and is causing significant pain, marking a concerning development in the former president's health condition.

Aug 8, 2026·4 sources
00
Aug 7, 2026

Scholar Rock Removes Novo Nordisk Indiana Facility from FDA Application for Rare Muscle Weakness Drug

Scholar Rock announced it will remove Novo Nordisk's (formerly Catalent's) Indiana manufacturing facility from its FDA biologics license application for a treatment targeting a rare neuromuscular disease. The regulatory filing adjustment comes as the company seeks approval for its muscle weakness therapy.

Aug 7, 2026·5 sources
00

BlossomHill Therapeutics raises $150 million in upsized oncology IPO

Oncology-focused biotech firm BlossomHill Therapeutics raised $150 million in an upsized U.S. initial public offering, though shares fell 1.6% in their trading debut.

Aug 7, 2026·2 sources
00

Study finds next-generation AI medical models still perpetuate racial and gender stereotypes

Flinders University researchers evaluated two advanced reasoning large language models—o3-mini and DeepSeek-R1—and discovered they continue to reproduce racial and gender stereotypes when describing fictional patients with common medical conditions, despite being newer generation AI systems.

Aug 7, 2026·1 source
00

New Pulse Oximeter Technology Adapts to Different Skin Tones

Researchers have developed an improved pulse oximeter that adjusts for variations in skin color, addressing longstanding accuracy concerns with traditional devices that have been used for decades to measure blood oxygen levels.

Aug 7, 2026·1 source
00

Multistate salmonella outbreak linked to fresh jalapeño peppers under investigation

U.S. health authorities are investigating a multistate outbreak of salmonella javiana infections linked to fresh jalapeño peppers. The investigation is being conducted jointly by federal health agencies.

Aug 7, 2026·2 sources
00

FDA Schedules Advisory Committee Meeting for Grail's Galleri Multi-Cancer Screening Test

The U.S. Food and Drug Administration will convene its Molecular and Clinical Genetics Panel on September 23, 2026, to review Grail's premarket approval application for Galleri, a multi-cancer early detection test. The advisory committee meeting represents a critical regulatory milestone for the company, which anticipates a potential approval decision in early 2027.

Aug 7, 2026·16 sources
00

FDA Schedules Advisory Committee Meeting for Grail's Galleri Multi-Cancer Screening Test

The U.S. Food and Drug Administration will convene its Molecular and Clinical Genetics Panel on September 23, 2026, to review Grail's premarket approval application for Galleri, a multi-cancer early detection test. The advisory committee meeting represents a critical regulatory milestone for the company, which anticipates a potential approval decision in early 2027.

Aug 7, 2026·9 sources
00
Aug 6, 2026

FDA approves Replimune's melanoma drug after two prior rejections

The FDA granted accelerated approval to Replimune's TUDRIQEVTM (vusolimogene oderparepvec-wtpg) for melanoma treatment, reversing two earlier rejections following support from an advisory panel. The approval marks a significant turnaround for the biotech company after a tumultuous regulatory process.

Aug 6, 2026·3 sources
00

Scientists Discover Immune Cell Migration from Blood to Brain Beginning at Age 50

Researchers have overturned long-held scientific understanding by discovering that aging human brains undergo a massive influx of peripheral blood-derived immune cells starting around age 50, replacing resident microglia with more inflammatory cells. This shift may help explain how normal aging sets the stage for Alzheimer's disease and dementia.

Aug 6, 2026·5 sources
00

Intellia Therapeutics Reports Positive Phase 3 Results for HAE Treatment, Plans 2027 U.S. Launch

Intellia Therapeutics announced second quarter 2026 financial results alongside positive Phase 3 clinical data for lonvo-z in hereditary angioedema (HAE), with FDA biologics license application acceptance anticipated in late 2026 and U.S. commercial launch planned for first half of 2027.

Aug 6, 2026·2 sources
00

Child dies in Chinese gene-editing trial for Duchenne muscular dystrophy, raising safety and transparency concerns

A child has died during a gene-editing clinical trial in China conducted by a Chinese startup for Duchenne muscular dystrophy treatment, reigniting debate about regulatory oversight and transparency in the country's biotech sector.

Aug 6, 2026·2 sources
00

FDA approves Moderna's mFlusiva, first mRNA-based flu vaccine in the United States

The Food and Drug Administration approved Moderna's mFlusiva on Wednesday, marking the first mRNA-based influenza vaccine authorized in the U.S. The vaccine is approved for adults aged 50 and older, representing a significant expansion of mRNA technology beyond COVID-19 vaccines.

Aug 6, 2026·6 sources
00

Over 200 Deaths Linked to Weight Loss Drugs in UK, Regulatory Data Shows

The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has reported that more than 200 deaths have been linked to weight loss medications including Wegovy and Mounjaro, with the majority associated with tirzepatide. The data also shows approximately 18,000 adverse reactions have been reported.

Aug 6, 2026·3 sources
00
Aug 5, 2026

Mounjaro Found to Reduce Heart Attack Risk by 33% in Type 2 Diabetes Patients with Heart Disease

A new study shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist drug, reduces heart attack risk by 33% when added to standard care for patients with both type 2 diabetes and existing heart disease. The findings come as worldwide sales of the drug doubled to £13.8 billion in the first half of 2026.

Aug 5, 2026·5 sources
00

FDA approves Takeda's Orzeyful, first orexin agonist drug for narcolepsy type 1

The FDA has approved Takeda's Orzeyful (orexin agonist) for treating narcolepsy type 1 in adults, marking the first approval in a new class of sleep medicines that addresses the full range of narcolepsy symptoms. The approval is expected to reshape the treatment paradigm and launch a closely watched commercial drug race.

Aug 5, 2026·5 sources
00

UK Approves First Trial of Moderna-Oxford mRNA Vaccine to Prevent Lynch Syndrome Cancers

UK regulators have authorized the INTERCEPT-Lynch Phase 1/2 trial of mRNA-4194, a preventive cancer vaccine developed by Moderna and the University of Oxford targeting people with Lynch syndrome, an inherited condition affecting 1 in 300 people with up to 80% lifetime cancer risk. The trial will begin dosing in summer 2026.

Aug 5, 2026·9 sources
00

German Study Finds Cannabis-Derived Dronabinol Significantly Reduces Nightmares in PTSD Patients

A randomized controlled trial in Germany found that dronabinol, a cannabis-derived THC medication, significantly decreased nightmares in patients with post-traumatic stress disorder in a double-blind study published in Nature Medicine.

Aug 5, 2026·3 sources
00

Study finds severe COVID-19 can reactivate dormant viruses, potentially explaining long COVID

University of Texas at Austin researchers published findings in Nature showing that severe COVID-19 infections can reactivate dormant viruses like Epstein-Barr and cytomegalovirus in hospitalized patients, offering new insights into long COVID and autoimmune complications.

Aug 5, 2026·7 sources
00
Aug 4, 2026

Biotech Startup Abandons Plans to Scale Custom CRISPR Therapies

A startup that had promised to commercialize and scale personalized CRISPR gene-editing therapies has abruptly canceled its plans, marking a setback for the custom therapeutics sector.

Aug 4, 2026·1 source
00

FDA Authorizes Caristo's AI Tool for Cardiovascular Risk Assessment

The University of Oxford spinout Caristo has received FDA authorization for an AI-powered tool designed to assess heart attack risk in patients without obstructive coronary artery disease. The company plans to launch the cardiovascular risk predictor soon.

Aug 4, 2026·1 source
00

FDA Grants 510(k) Clearance to DeepHealth's AI-Powered Breast Ultrasound Analysis Platform

DeepHealth, a RadNet subsidiary, received FDA 510(k) clearance for an AI platform that automates breast ultrasound lesion detection, characterization according to ACR BI-RADS standards, and report generation. The technology aims to address the time-intensive, operator-dependent nature of ultrasound breast cancer screening.

Aug 4, 2026·7 sources
00

Moderna Begins First Human Trial of Vaccine Against Bundibugyo Ebola Strain Linked to Congo Outbreak

Moderna has initiated a Phase 1 clinical trial in Canada of mRNA-1469, an experimental vaccine targeting Bundibugyo ebolavirus, a strain of Ebola that has killed over 1,650 people and currently has no approved vaccine. Health Canada has authorized the trial and the first participants have already been vaccinated.

Aug 4, 2026·8 sources
00

UK breast cancer screening guidelines miss 95% of women under 50 who develop disease, study finds

Research from University of Cambridge and Institute of Cancer Research reveals that current NHS and NICE referral criteria fail to identify up to 95% of women under 50 who develop breast cancer within a decade. The study suggests a comprehensive risk assessment tool called BOADICEA identifies eight times more at-risk women than current family-history-based guidelines.

Aug 4, 2026·8 sources
00
Aug 3, 2026

Curium to take radiopharma company Lantheus private in $8 billion deal

Nuclear medicine company Curium has struck a deal to take Lantheus Holdings Inc. private in a transaction worth approximately $8 billion.

Aug 3, 2026·2 sources
00
Aug 2, 2026

CRISPR makes prostate cancer vulnerable to immunotherapy in mice

Scientists used CRISPR gene editing to make prostate cancer cells easier for the immune system to detect and destroy, dramatically improving immunotherapy effectiveness in mice.

Aug 2, 2026·1 source
00

Michigan Supreme Court Clears Path for Attorney General's Investigation into Eli Lilly Insulin Pricing

The Michigan Supreme Court ruled 4-3 on July 31, 2026, overturning two lower court decisions and allowing Attorney General Dana Nessel to proceed with an investigation into Eli Lilly's insulin pricing practices under the Michigan Consumer Protection Act.

Aug 2, 2026·6 sources
00
Aug 1, 2026

Eating less protein may slow aging and improve metabolism, major review finds

A comprehensive review of over 350 studies suggests that consuming less protein than currently popular may improve metabolism, reduce inflammation, and potentially slow aging processes.

Aug 1, 2026·1 source
00
Jul 31, 2026

FDA Advisory Committee Votes 10-3 in Favor of Replimune's RP1 Efficacy Data from Ignyte Study

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee determined that efficacy data from Replimune's Ignyte study for RP1 is evaluable and clinically meaningful, voting 10 to 3 in favor.

Jul 31, 2026·1 source
00

Scientists identify immune response that may explain statin muscle pain

Researchers have identified an immune response that may explain why statins cause muscle pain, weakness, and exercise intolerance in some patients. The finding could eventually lead to treatments that prevent these side effects.

Jul 31, 2026·1 source
00

Daily avocado consumption may lower heart disease risk in obese adults

A six-month clinical trial found that eating one avocado daily reduced the number of LDL particles circulating in the blood of adults with obesity, potentially lowering heart disease risk.

Jul 31, 2026·1 source
00

Novo Nordisk's experimental drug fails to reduce heart attacks and strokes in large study

Novo Nordisk's experimental inflammation-targeting drug failed to reduce the risk of heart attacks and strokes in a closely watched large clinical trial, a setback for the drugmaker's growth prospects beyond obesity and diabetes.

Jul 31, 2026·2 sources
00
Jul 30, 2026

Johnson & Johnson secures option to acquire CAR-T biotech Sail Biomedicines for $2.6 billion

J&J has obtained an option to purchase Sail Biomedicines, a Flagship Pioneering-backed startup developing 'in vivo' CAR-T therapies, in a deal valued at nearly $2.6 billion.

Jul 30, 2026·1 source
00
Jul 29, 2026

Latigo reports positive mid-stage trial results for pain drug competing with Vertex's Journavx

Latigo has announced successful mid-stage clinical trial results for its non-opioid pain medication, positioning it as a potential competitor to Vertex Pharmaceuticals' pain drug Journavx in a field historically marked by development failures.

Jul 29, 2026·1 source
00

FDA Advisory Panel Rejects Capricor's Deramiocel Cell Therapy for Duchenne Cardiomyopathy

An FDA advisory panel voted against approving Capricor's deramiocel, a cell therapy for Duchenne-related cardiomyopathy, determining the company had not sufficiently proven the treatment's benefits. The contentious decision could have broader implications for other rare disease drug developers.

Jul 29, 2026·1 source
00

US FDA Approves First Freeze-Dried Plasma Product

The U.S. Food and Drug Administration has approved the first freeze-dried plasma product, marking a significant regulatory milestone in blood product technology.

Jul 29, 2026·1 source
00

Brazil Approves Five New GLP-1 Diabetes Drugs Following Ozempic Patent Expiration

Brazil's health regulator Anvisa approved five new injectable GLP-1 drugs for diabetes and obesity treatment, following expedited regulatory reviews after Ozempic's patent expired in the country in March 2026.

Jul 29, 2026·1 source
00
Jul 28, 2026

Brazilian study finds father's pre-conception diet affects newborn body composition

Research examining 43 family triads in Ribeirão Preto, São Paulo, Brazil demonstrates that a father's diet before conception can influence their children's health and body composition, adding to evidence of paternal health impacts on offspring.

Jul 28, 2026·1 source
00

New research identifies Axl receptor blocking as potential treatment for osteoporosis

Scientists have discovered that blocking the Axl receptor may offer a novel approach to promoting bone formation, potentially providing a new treatment avenue for osteoporosis, a common age-related disease affecting millions worldwide.

Jul 28, 2026·1 source
00

University researchers develop new human tissue model to study glioblastoma infiltration

Scientists at the University have created a new human tissue model that tracks how glioblastoma, an aggressive brain tumor, infiltrates surrounding brain tissue. The research aims to address the challenge of tumor recurrence after surgery, when remaining cells cause the cancer to return.

Jul 28, 2026·1 source
00

Remdesivir treatment reduces cardiovascular complications in kidney transplant recipients with COVID-19

Study finds that kidney transplant recipients treated with remdesivir within a week of COVID-19 diagnosis and receiving at least three consecutive days of therapy experienced fewer cardiovascular complications compared to those who did not receive the antiviral treatment.

Jul 28, 2026·1 source
00

FDA staff reiterate concerns about Replimune skin cancer treatment ahead of advisory meeting

FDA staff raised ongoing concerns about Replimune's experimental skin cancer therapy in briefing documents released before an advisory committee meeting, questioning the treatment's efficacy data.

Jul 28, 2026·1 source
00

Cyclosporiasis outbreak in U.S. surpasses 11,000 cases as FDA defends food safety system

A major cyclosporiasis outbreak has infected over 11,000 Americans, with Michigan reporting more than 10,000 cases. FDA officials are defending the safety of the U.S. food supply while experts point to vulnerabilities in the food safety tracking system.

Jul 28, 2026·3 sources
00

GSK partner Hansoh Pharmaceutical's bone cancer drug meets primary endpoint in second Phase III trial in China

Hansoh Pharmaceutical announced positive results from the ARTEMIS-011 Phase III trial in China, with its experimental drug Ris-Rez meeting the primary endpoint of progression-free survival in relapsed bone cancer patients. This marks the second Phase III success for the drug, strengthening GSK's oncology portfolio through its licensing partnership with the Chinese biotech.

Jul 28, 2026·3 sources
00
Jul 27, 2026

Chinese Drugmaker Innocare Reports Positive Late-Stage Trial Results for Psoriasis Oral Treatment

Innocare Pharma announced its experimental oral drug for moderate-to-severe plaque psoriasis showed consistent treatment effects in late-stage clinical trials, entering a competitive market where recent head-to-head studies have compared efficacy of various psoriasis treatments.

Jul 27, 2026·3 sources
00

ICMR licenses cervical cancer drug SHetA2 to Emcure Pharmaceuticals for development in India

India's ICMR has licensed SHetA2, an experimental drug that aims to prevent HPV from turning cancerous, to Emcure Pharmaceuticals for development. The move addresses India's significant cervical cancer burden, with approximately 123,907 new cases and 77,348 deaths annually.

Jul 27, 2026·3 sources
00

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.

Jul 27, 2026·4 sources
00
Jul 26, 2026

Phase 2 Clinical Trial Shows THC-CBD Combination Rapidly Reduces Agitation in Advanced Dementia Patients

The LiBBY clinical trial found that a combination of CBD and THC rapidly and significantly reduced agitation in hospice-eligible dementia patients, with nearly 90% of participants showing behavioral improvement in the nationwide study.

Jul 26, 2026·3 sources
00

Daily fiber supplement reduced knee arthritis pain and improved strength in clinical trial

A six-week trial found that a prebiotic fiber supplement reduced knee osteoarthritis pain while also improving grip strength and pain sensitivity, suggesting a gut-muscle-pain connection.

Jul 26, 2026·1 source
00

Scientists revive vancomycin antibiotic by pairing it with second drug to overcome resistance

Researchers found a way to restore the effectiveness of vancomycin against resistant bacteria by combining it with another compound, rather than developing an entirely new antibiotic.

Jul 26, 2026·1 source
00
Jul 25, 2026

FDA's voluntary sodium reduction targets show minimal impact three years after implementation

The U.S. Food and Drug Administration's Phase I voluntary sodium reduction targets, issued in 2021 to encourage manufacturers to lower sodium in packaged foods by 2024, appear to have had minimal effect on reducing sodium levels in food products.

Jul 25, 2026·1 source
00

Colorectal cancer becomes leading cause of cancer death in adults under 50

Colorectal cancer has become the leading cause of cancer death among people under 50, with cases continuing to rise in younger adults. Warning signs include persistent bowel changes, recurring rectal bleeding, and abdominal pain.

Jul 25, 2026·2 sources
00

Engineered probiotic bacteria show promise in boosting immune response against pancreatic cancer

Researchers have developed engineered probiotic bacteria designed to overcome the 'cold' tumor microenvironment in pancreatic cancer, potentially enhancing the effectiveness of immunotherapy treatments for this difficult-to-treat disease.

Jul 25, 2026·1 source
00
Jul 24, 2026

FDA Approves Outlook Therapeutics' LYTENAVA as First Branded Bevacizumab for Wet AMD After Fourth Attempt

The U.S. Food and Drug Administration has approved LYTENAVA (bevacizumab-vikg) for treating neovascular age-related macular degeneration (wet AMD), marking the first FDA-approved ophthalmic formulation of bevacizumab after 20 years of off-label use. The approval comes on Outlook Therapeutics' fourth regulatory attempt, though the company faces cash constraints as it enters commercialization.

Jul 24, 2026·8 sources
00

Federal Judge Orders FDA to Reconsider Mifepristone Prescribing Restrictions

A U.S. federal judge ruled that Biden-era FDA restrictions on prescribing the abortion drug mifepristone are unlawful and unjustified, ordering the Trump Administration to reconsider existing regulations. The decision comes as over 400 state lawmakers from all 50 states have signed an amicus brief demanding protection for telehealth abortion care access.

Jul 24, 2026·4 sources
00

11-Year-Old London Girl Becomes First UK Patient to Receive Gene Therapy for Rare Sight-Robbing Condition

Catherine L'Estrange from North Acton became the first patient in the UK and second in the world to receive groundbreaking gene therapy for Bardet-Biedl syndrome, a rare condition that progressively causes blindness in children. The treatment, performed at St Helier Hospital in March, involves injecting healthy copies of a gene directly into the eye.

Jul 24, 2026·5 sources
00

Study Identifies Germline Variants Linked to Yescarta CAR-T Toxicity and Expansion

New research analyzing patients from Kite Pharma's Yescarta clinical trials has identified inherited genetic signatures that can predict which patients are at higher risk for toxic side effects from CAR-T cell therapy, potentially enabling better patient selection and monitoring for this cancer immunotherapy.

Jul 24, 2026·4 sources
00

Investigation Reveals Unreported Child Death in China’s First Brain-Directed CRISPR Trial

A 6-year-old girl died after receiving experimental gene-editing therapy for a non-life-threatening neurodevelopmental condition in Shanghai, with her death kept secret until uncovered by an investigation by Science and Retraction Watch. The family reportedly paid over $800,000 for the treatment.

Jul 24, 2026·6 sources
00

EU Regulator Backs First Oral IL-23 Receptor Drug for Plaque Psoriasis

The European Medicines Agency has recommended granting marketing authorization for Icotyde (icotrokinra), the first oral medication targeting the interleukin-23 receptor, for treating moderate-to-severe plaque psoriasis in adults and adolescents aged 12 years and older in the European Union.

Jul 24, 2026·1 source
00

Japanese Researchers Discover Sulfur Compound That May Slow Age-Related Muscle Loss

Scientists at Kyushu University in Japan have identified a sulfur-based compound called LASSS that protects and enhances a key muscle-repair protein called HGF, potentially offering a way to combat the muscle deterioration that occurs with aging. The compound appears to shield the protein from age-related chemical damage and more than double its strength.

Jul 24, 2026·7 sources
00

Genetic breakthrough reveals hidden causes of severe morning sickness in pregnancy

Scientists have identified major genetic factors underlying hyperemesis gravidarum, the severe pregnancy nausea and vomiting condition that affects some women.

Jul 24, 2026·1 source
00

FDA Approves First Over-the-Counter Combination Pill of Tylenol and Naproxen for Pain Relief

The U.S. Food and Drug Administration approved a nonprescription fixed-dose combination pill containing acetaminophen (650 mg) and naproxen sodium (220 mg), marketed as Tylenol with Naproxen by Kenvue. The medication provides up to 12 hours of pain relief for patients aged 12 and older.

Jul 24, 2026·9 sources
00
Jul 23, 2026

Advanced Testing Methods Show Promise in Detecting Lung Cancer Biomarkers and Monitoring Disease

New research demonstrates that RNA-based testing can improve detection of MET exon 14 skipping mutations in lung cancer patients, while circulating tumor DNA (ctDNA) testing is increasingly being adopted for early cancer detection and treatment monitoring across oncology.

Jul 23, 2026·2 sources
00

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.

Jul 23, 2026·3 sources
00

European Commission Approves AstraZeneca's Etcamah for ER-Positive Breast Cancer with ESR1 Mutations

The European Commission has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for first-line treatment of adults with ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The approval is based on SERENA-6 Phase III trial results showing a 56% reduction in risk of disease progression or death.

Jul 23, 2026·9 sources
00
Jul 22, 2026

FDA Investigating New Cyclospora Outbreak With 72 Cases, Source Not Yet Identified

The U.S. Food and Drug Administration announced it is investigating a new outbreak of cyclosporiasis involving 72 reported cases. The source of the parasitic infection, which causes severe gastrointestinal illness, has not yet been identified and is separate from previously recalled lettuce.

Jul 22, 2026·7 sources
00

GSK receives FDA approval for Jideytro lung cancer drug

The FDA approved GSK's Jideytro for treating a form of lung cancer, nearly two months after the British drugmaker acquired the treatment as part of a $10.6 billion deal.

Jul 22, 2026·1 source
00

FDA panel votes to allow compounding of peptide BPC-157

FDA advisory panel voted to place peptide BPC-157 on a list allowing broader pharmacy compounding, the first of seven peptides under review. The decision supports HHS Secretary RFK Jr.'s push to expand access to these compounds.

Jul 22, 2026·6 sources
00

Johnson & Johnson receives FDA approval for soft tissue surgical robot

After more than a decade of development, J&J's robotic surgery device received FDA marketing authorization, allowing the healthcare conglomerate to enter the competitive surgical robotics market.

Jul 22, 2026·2 sources
00

Repligen acquires BioLife Solutions in $1.5 billion deal to expand cell therapy business

Repligen Corp announced it will acquire BioLife Solutions in a cash-and-stock transaction valued at approximately $1.5 billion. The deal expands Repligen's presence in the fast-growing cell therapy market.

Jul 22, 2026·1 source
00

FDA Selects Dexcom as First Participant in TEMPO Digital Health Device Pilot Program

The U.S. Food and Drug Administration announced Dexcom as the inaugural manufacturer selected for its Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot, which coordinates with CMS's outcomes-based ACCESS model to align device market entry and reimbursement processes.

Jul 22, 2026·5 sources
00

Science Corp’s PRIMA Retinal Implant Receives CE Mark for European Commercial Launch

Science Corporation has received CE mark approval and begun commercial launch in Europe of PRIMA, a retinal implant that restores functional central vision to patients with geographic atrophy caused by age-related macular degeneration. The device could launch in the U.S. in 2027.

Jul 22, 2026·4 sources
00
Jul 21, 2026

Nearly All US Heart Disease Deaths Linked to Modifiable Risk Factors, New Research Shows

A new study published in JAMA Cardiology reveals that approximately 90% of ischemic heart disease deaths in the United States remain attributable to modifiable risk factors including blood pressure, diet, and LDL cholesterol, despite significant declines in mortality since 1990. Research also shows these factors are linked to unstable coronary artery plaques that lead to heart attacks.

Jul 21, 2026·4 sources
00

Japanese Phase 1 Trial Supports Medium-Term Safety of iPSC-Derived Neural Stem/Progenitor Cell Therapy for Spinal Cord Injury

A Phase 1 clinical trial in Japan reported no tumor formation or graft-related adverse events after transplanting iPSC-derived neural stem/progenitor cells into four patients with subacute complete cervical spinal cord injuries during two to four years of follow-up. The small, uncontrolled study was designed primarily to assess safety and was not able to establish treatment efficacy.

Jul 21, 2026·3 sources
00

Broad Institute, Boston Children's Hospital, and Jackson Laboratory Launch $160 Million Center for Rare Disease Gene Therapies

Three major research institutions announced the creation of the Center for Therapeutic Genetics, a nonprofit collaboration aimed at developing standardized genetic medicines, including base and prime editing, for rare and ultra-rare diseases that currently lack treatments.

Jul 21, 2026·9 sources
00

Gilead Sciences and Merck's Once-Weekly HIV Pill Maintains Viral Suppression in Phase 3 Trials

Gilead Sciences and Merck announced that their experimental once-weekly HIV pill combining islatravir and lenacapavir successfully maintained viral suppression at 48 weeks in two Phase 3 trials (ISLEND-1 and ISLEND-2) involving 1,209 adults with virologically suppressed HIV. The results support regulatory filings for what could become the first once-weekly oral HIV treatment regimen.

Jul 21, 2026·7 sources
00

Study Finds Stuffed Toys Release PFAS 'Forever Chemicals' Into Children's Saliva

New research published in the Journal of Exposure Science & Environmental Epidemiology found that all 18 tested stuffed toys released at least one type of PFAS into artificial saliva under conditions simulating children mouthing the toys, with PFHxA being the primary compound detected.

Jul 21, 2026·4 sources
00
Jul 20, 2026

Largest genetic study of borderline personality disorder identifies 11 risk regions and 9 genes

An international research team led by the Central Institute of Mental Health in Mannheim has published the largest genome-wide association study on borderline personality disorder to date, analyzing data from approximately 13,000 individuals and identifying 11 genetic locations and 9 genes associated with the condition. The findings, published in Nature Genetics on July 20, 2026, represent the first significant genetic clues for this complex mental health disorder.

Jul 20, 2026·2 sources
00
Jul 18, 2026

FDA retracts cyclospora finding in Taylor Farms lettuce as false positive

The FDA apologized and confirmed that laboratory results showing cyclospora parasite in Taylor Farms lettuce samples were false positives after re-testing, as investigation into the outbreak affecting over 5,000 cases continues.

Jul 18, 2026·4 sources
00

Fluvoxamine shows promise for long COVID fatigue in clinical trial

A randomized clinical trial of 399 adults found that the low-cost antidepressant fluvoxamine significantly reduced fatigue and improved quality of life in people struggling with long COVID symptoms.

Jul 18, 2026·1 source
00
Jul 17, 2026

GSK halts development of chronic cough drug after late-stage trial failures

GSK discontinued development of an experimental chronic cough treatment after it failed to meet key goals in two late-stage clinical trials, with the company stating it was unlikely to transform patient care. Shares fell about 4%.

Jul 17, 2026·2 sources
00
Jul 16, 2026

Kalshi launches prediction markets for clinical trials and FDA drug approvals

Prediction market platform Kalshi will begin taking bets on the outcomes of clinical trials and FDA regulatory reviews, making drug-development odds public for the first time and expanding into biotechnology.

Jul 16, 2026·3 sources
00

Merck wins FDA approval for first oral PCSK9 cholesterol pill

Merck received FDA approval for its oral PCSK9 inhibitor cholesterol pill, the first of its kind, offering a more convenient alternative to existing injectable therapies for high-risk patients.

Jul 16, 2026·4 sources
00
Jul 15, 2026

Blood Test Using P-Tau217 Biomarker Can Predict Alzheimer's Risk Years Before Symptoms Appear, Study Finds

A new study demonstrates that a blood test measuring p-tau217 levels can identify healthy older adults at high risk of developing Alzheimer's symptoms within five to 10 years, potentially enabling early intervention as prevention trials advance.

Jul 15, 2026·5 sources
00
Jul 14, 2026

Study finds frailty risks with GLP-1 drugs in older adults

A large study found potential signs of frailty in older adults taking Eli Lilly's Zepbound may signal relatively high risks for adverse outcomes, raising concerns about GLP-1 obesity drug use in elderly populations.

Jul 14, 2026·1 source
00

FDA Approves Celcuity's Revtorpyk (Gedatolisib) for Advanced Breast Cancer

The U.S. Food and Drug Administration has approved Revtorpyk (gedatolisib), Celcuity's first drug to reach market, for treating hormone receptor positive, HER2 negative advanced breast cancer. The approval sent the company's shares up 7% in extended trading.

Jul 14, 2026·4 sources
00

AstraZeneca Acquires Lung Cancer Drug from China's Dizal Pharmaceutical in $1.5 Billion Deal

AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to a lung cancer drug, with total deal value reaching $1.5 billion including milestone payments. The drug is commercial-ready and adds to AstraZeneca's oncology franchise.

Jul 14, 2026·2 sources
00

Experimental Alzheimer's drug targeting tau protein shows promise in slowing cognitive decline

An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.

Jul 14, 2026·8 sources
00

Semaglutide may slow biological aging in adults with HIV

Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.

Jul 14, 2026·1 source
00

Eating chili peppers linked to substantially higher esophageal cancer risk

A major review found that people who consumed the most chili peppers had a substantially higher risk of esophageal cancer, though evidence was less clear for stomach and colorectal cancers.

Jul 14, 2026·1 source
00
Jul 13, 2026

FDA Urges Infant Formula Industry to Strengthen Supplier Oversight Following Botulism Outbreaks and Recalls

The U.S. Food and Drug Administration issued a letter to infant formula manufacturers calling for enhanced supply chain oversight after two botulism outbreaks—the first in nearly 50 years linked to baby formula in the U.S.—and a global cereulide contamination event prompted multiple product recalls.

Jul 13, 2026·2 sources
00

Oxford Launches First Human Trial of Bundibugyo Ebola Vaccine Amid Congo Outbreak

The University of Oxford has begun the first human trial of a vaccine targeting Bundibugyo ebolavirus, accelerating efforts to combat an ongoing outbreak in the Democratic Republic of Congo. A US patient infected in Congo is being treated at a German hospital.

Jul 13, 2026·2 sources
00

GSK's Cancer Drug Jemperli Meets Primary Goal in Mid-Stage Rectal Cancer Trial

GSK announced its cancer drug Jemperli achieved clinically significant rates of patients showing no detectable signs of cancer for one year or more in a mid-stage rectal cancer trial.

Jul 13, 2026·1 source
00

Record-Breaking May and June Heatwaves Linked to Over 2,700 Deaths in England and Wales, 10,000 Across Europe

Scientists estimate that unprecedented heatwaves in May and June 2026 caused more than 2,700 excess deaths in England and Wales, with approximately 440 deaths per day during the June heatwave's three-day peak. Across Europe, the extreme heat resulted in over 10,000 excess deaths, with researchers attributing the severity to a 'heat dome' worsened by human-induced climate change.

Jul 13, 2026·3 sources
00

HHS & VA Partner to Advance Psychedelic Therapies for Veterans

HHS and the VA signed a five-year Memorandum of Understanding on July 13, 2026, to collaborate on research, clinical development, and deployment of rapid-acting psychedelic drug products for veterans with serious mental illness and substance use disorders, pending FDA approval.

Jul 13, 2026·1 source
00
Jul 10, 2026

EU Regulator Warns Desogestrel and Etonogestrel Contraceptives Carry Small Brain Tumor Risk

The European Medicines Agency safety committee announced that commonly used contraceptives containing desogestrel and etonogestrel carry a small increased risk of meningioma after prolonged use.

Jul 10, 2026·1 source
00
Jul 9, 2026

FDA Approves First Wearable On-Body Injector for Cancer Drug Delivery with Sanofi's Sarclisa

The FDA has approved Sanofi's Sarclisa (isatuximab) for subcutaneous delivery via a wearable on-body injector, marking the first cancer drug to receive approval for this delivery method. The device offers multiple myeloma patients a less burdensome alternative to intravenous infusions.

Jul 9, 2026·6 sources
00

ARPA-H Launches $160 Million Gene Editing Drug Development Program

The Advanced Research Projects Agency for Health (ARPA-H) has launched a $160 million initiative to fund seven groups over five years to develop custom gene editing drugs, aiming to replicate successes like the Baby KJ case.

Jul 9, 2026·1 source
00

AstraZeneca and Ionis' heart disease drug Wainua fails pivotal trial, shares plunge

AstraZeneca's shares fell as much as 9% after Wainua, a drug developed with Ionis Pharmaceuticals, unexpectedly failed to meet its primary endpoint in a late-stage trial for ATTR-CM heart disease. The failure has raised concerns about the company's trial design and shaken investor confidence.

Jul 9, 2026·4 sources
00
Jul 8, 2026

Northwestern Medicine study shows lung transplants can extend survival for patients with advanced lung cancer

A landmark study from Northwestern Medicine published July 8, 2026, demonstrates that lung transplants can successfully extend survival for select patients with Stage 4 lung cancer that hasn't spread beyond the lungs, challenging the long-held belief that transplanting organs into advanced cancer patients is too risky.

Jul 8, 2026·4 sources
00

FDA approves Johnson & Johnson's dual-energy cardiac ablation catheter combining radiofrequency and pulsed field technology

The FDA has approved J&J's ThermoCool SmartTouch SF Platform, allowing electrophysiologists to switch between radiofrequency and pulsed field energy through a single catheter integrated with the Carto mapping system. U.S. physicians are expected to begin using the device this summer.

Jul 8, 2026·4 sources
00

AstraZeneca and Daiichi Sankyo Near UK Pricing Agreement for Breast Cancer Drug Enhertu

AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with the UK's National Institute for Health and Care Excellence (NICE) for their breast cancer treatment Enhertu, which could provide access to women in England and Wales with HER2-low breast cancer.

Jul 8, 2026·2 sources
00

WHO Warns Global Cancer Cases Could Nearly Double to 35 Million Annually by 2050

The World Health Organization released its Global Status Report on Cancer 2026, projecting annual cancer cases will surge from 20.6 million currently to 35 million by 2050—a 66.7% increase—while the disease already claims over 26,000 lives daily. The report highlights the devastating physical, emotional, and financial toll on millions of patients despite scientific progress.

Jul 8, 2026·9 sources
00

Silica nanoparticles eliminate aggressive prostate cancer in mice

Engineered silica nanoparticles caused prostate cancer tumor cells to self-destruct and activated immune response in preclinical mouse studies. Combined with immunotherapy, the treatment showed promising results against aggressive disease.

Jul 8, 2026·1 source
00
Jul 7, 2026

FDA Approves Vera Therapeutics' TRUTAKNA for IgA Nephropathy Treatment

The U.S. Food and Drug Administration has granted accelerated approval to Vera Therapeutics' drug TRUTAKNA for treating adult patients with primary IgA nephropathy, a potentially life-threatening chronic autoimmune kidney disease. The approval sent Vera's shares up 6.8% in afternoon trading.

Jul 7, 2026·3 sources
00

European Medicines Agency Fast-Tracks Review of Revolution Medicines' Experimental Pancreatic Cancer Pill

The EMA has granted accelerated assessment to Revolutions' experimental pancreatic cancer drug, potentially shortening the review timeline for this treatment targeting a disease with limited therapeutic options.

Jul 7, 2026·1 source
00
Jul 6, 2026

Study Finds Nearly 1 in 4 Adults Test Positive for Alpha-Gal Antibodies in Five High-Risk States

A new study published in Morbidity and Mortality Weekly Report reveals that approximately 24% of adults in five states with high rates of alpha-gal syndrome, including Missouri, test positive for antibodies associated with the tick-borne condition.

Jul 6, 2026·2 sources
00
Jul 2, 2026

Roche's divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 lung cancer trial

Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.

Jul 2, 2026·4 sources
00

FDA Expands Casgevy Gene Therapy Approval to Children as Young as Two with Sickle Cell Disease and Beta Thalassemia

The FDA has approved Vertex Pharmaceuticals' Casgevy (exagamglogene autotemcel) for patients aged two years and older with sickle cell disease and transfusion-dependent beta thalassemia, expanding from the previous minimum age of 12 years. The approval was granted under the agency's Commissioner's National Priority Voucher program.

Jul 2, 2026·3 sources
00
Jun 30, 2026

FDA Authorizes Philip Morris to Market Zyn Nicotine Pouches as Less Harmful Than Cigarettes

The U.S. Food and Drug Administration granted Philip Morris permission to market its Zyn nicotine pouches as less harmful than cigarettes, allowing the company to market 20 variants of the product with modified risk claims.

Jun 30, 2026·3 sources
00

BeOne Medicines' Brukinsa Meets Primary Endpoint in Phase 3 Frontline Mantle Cell Lymphoma Trial

BeOne Medicines announced positive Phase 3 results from the MANGROVE trial, showing Brukinsa plus rituximab reduced the risk of disease progression or death by 43% compared to bendamustine plus rituximab in frontline mantle cell lymphoma patients. The combination represents a potential chemotherapy-free treatment option.

Jun 30, 2026·4 sources
00
Jun 29, 2026

FDA peptide advisory panel to include doctors and pharmacists with financial ties to unproven peptide industry

U.S. health officials have appointed doctors and pharmacists with deep financial connections to the peptide industry to an FDA advisory panel that will reconsider controversial peptide drugs next month. The appointments raise ethics concerns given the panelists could benefit from regulatory changes they help shape.

Jun 29, 2026·5 sources
00

AbbVie and Genmab's Epkinly Combination Meets Primary Endpoint in Phase 3 Trial for Relapsed/Refractory DLBCL

The EPCORE DLBCL-4 Phase 3 trial showed that epcoritamab (Epkinly) combined with lenalidomide significantly improved progression-free survival compared to R-GemOx chemotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy. The results bring the bispecific antibody closer to a potential label expansion.

Jun 29, 2026·6 sources
00

New England Journal of Medicine Retracts Amgen's Tavneos Clinical Trial Amid Data Manipulation Allegations

The New England Journal of Medicine retracted the main clinical trial used to approve Amgen's $500 million drug Tavneos, following allegations of data manipulation. The European Medicines Agency had previously recommended revoking the drug's approval over data integrity concerns.

Jun 29, 2026·1 source
00

FDA Selects Eli Lilly and Regeneron for Pilot Program to Accelerate Manufacturing Facility Reviews

The FDA selected seven companies including Eli Lilly and Regeneron for a pilot program designed to speed up reviews of new domestic pharmaceutical manufacturing facilities, aiming to strengthen U.S. drug supply chains.

Jun 29, 2026·2 sources
00

Zymeworks Acquires Theravance Biopharma for $929 Million to Expand Beyond Cancer

Cancer-focused drugmaker Zymeworks will acquire Theravance Biopharma for $929 million in cash, marking its entry into the respiratory disease segment and expanding beyond its oncology focus.

Jun 29, 2026·2 sources
00
Jun 26, 2026

GLP-1 Drugs Linked to Smell and Taste Impairment in Diabetes Patients

New research has identified a connection between GLP-1 medications and impairment of smell and taste in diabetes patients, adding to the growing list of side effects associated with this drug class.

Jun 26, 2026·1 source
00

European Medicines Agency Recommends Revoking Amgen's Tavneos Over Data Integrity Issues

The European Medicines Agency recommended withdrawing marketing authorization for Amgen's rare autoimmune disease drug Tavneos, citing allegedly incorrect and misleading data used in the approval process and lack of benefits outweighing risks.

Jun 26, 2026·3 sources
00

FDA Approves Viridian Therapeutics' Lumvoa for Thyroid Eye Disease, Creating Competition with Amgen's Tepezza

The U.S. Food and Drug Administration has approved Viridian Therapeutics' Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease, marking the first FDA-approved treatment for the condition and setting up direct competition with Amgen's blockbuster drug Tepezza.

Jun 26, 2026·5 sources
00
Jun 25, 2026

Supreme Court Blocks Thousands of Lawsuits Against Bayer Over Roundup Cancer Claims

The U.S. Supreme Court ruled 7-2 in favor of Bayer's Monsanto division, blocking thousands of state-level lawsuits alleging the company failed to warn consumers that Roundup weedkiller could cause cancer. The decision establishes that federal pesticide labeling law preempts state liability claims.

Jun 25, 2026·9 sources
00
Jun 24, 2026

FDA authorized to hire 2,200 workers after cutting over 3,000 jobs in 2025

The U.S. Food and Drug Administration has been authorized to hire 2,200 people to rebuild its workforce after cutting more than 3,000 employees last year. The agency has secured 600 new hires so far and is seeking 1,600 more positions.

Jun 24, 2026·5 sources
00

FDA approves Trodelvy for first-line triple-negative breast cancer

The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.

Jun 24, 2026·3 sources
00

Ollin Biosciences Raises $330 Million for Late-Stage Eye Disease Drug Trials

Texas-based biotech Ollin Biosciences secured $330 million in funding to advance late-stage clinical studies of its experimental eye disease treatment, representing one of the largest recent funding rounds in ophthalmology.

Jun 24, 2026·2 sources
00

France Reports First Ebola Case Linked to Congo Outbreak in Returning Doctor

A doctor who recently returned to France from a humanitarian mission in the Democratic Republic of Congo has tested positive for Ebola, marking France's first confirmed case linked to the current outbreak. This represents the first known international spread of the Bundibugyo strain outbreak.

Jun 24, 2026·1 source
00
Jun 23, 2026

US Provides Experimental Ebola Treatment for Clinical Trials in Congo Outbreak

The United States has supplied doses of an experimental antibody drug from Mapp Biopharmaceutical to support clinical trials addressing the expanding Ebola outbreak in the Democratic Republic of Congo, according to a Health Department spokesperson.

Jun 23, 2026·2 sources
00
Jun 22, 2026

US Announces Clinical Trial Reforms to Accelerate Drug Research and Counter China Competition

The FDA and HHS are implementing sweeping reforms to speed up early-stage drug research in the United States, addressing concerns that pharmaceutical companies have increasingly moved clinical trials to countries like China and Australia. HHS Secretary Robert F. Kennedy Jr. announced the changes aimed at bringing investment back to the U.S.

Jun 22, 2026·2 sources
00

China Approves World's First CAR-T Therapy for Solid Tumors to Treat Advanced Gastric Cancer

China's National Medical Products Administration has approved satricabtagene autoleucel (Satri-cel, CT041, Kaileimei®), marking the first CAR-T cell therapy approved globally for treating solid tumors, specifically for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.

Jun 22, 2026·4 sources
00

Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.

Jun 22, 2026·2 sources
00

FDA Reverses Rejection of Regenxbio's Rare Disease Gene Therapy

The FDA indicated it would reverse its earlier rejection of Regenxbio's gene therapy for a deadly childhood disease, stating that existing data would be sufficient to support an accelerated approval bid. The reversal represents a significant policy shift.

Jun 22, 2026·2 sources
00
Jun 18, 2026

Midjourney Announces Pivot to Medical Hardware with Full-Body Ultrasonic Scanner Project

AI image generation company Midjourney has announced Midjourney Medical, a new venture to develop full-body scanners that can map internal anatomy in 60 seconds, along with medical spa facilities where patients would receive scans.

Jun 18, 2026·3 sources
00
Jun 17, 2026

GLP-1 Diabetes Drugs Linked to Smell and Taste Impairment, Study Finds

New research published in JAMA Otolaryngology analyzing health records from nearly 900,000 patients suggests long-term use of GLP-1 drugs like Ozempic and Mounjaro for diabetes management is associated with increased risks of smell and taste disturbances, though experts note these side effects are not common.

Jun 17, 2026·4 sources
00

FDA Cracks Down on Unapproved Peptide Therapies and Compounding Pharmacies

FDA issues warning letters to telehealth companies and compounding pharmacies over illegal marketing of unapproved peptide products.

Jun 17, 2026·5 sources
00
Jun 15, 2026

FDA Approves Colorado's Plan to Import Cheaper Prescription Drugs from Canada

The FDA has approved Colorado's proposal to import prescription drugs from Canada at lower prices, marking a significant step in state-level efforts to reduce drug costs for residents.

Jun 15, 2026·1 source
00

Brain implant enables ALS patient to communicate for nearly two years, generating 2 million words

Casey Harrell, a 42-year-old man with ALS who lost his ability to speak, has successfully used a brain-computer interface for almost three years to communicate and control his computer, producing approximately 2 million words. The at-home brain implant represents a significant milestone in assistive technology for neurodegenerative disease patients.

Jun 15, 2026·3 sources
00
Jun 12, 2026

FDA Approves Belzutifan Plus Pembrolizumab as Adjuvant Therapy for Clear Cell Renal Cell Carcinoma

The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.

Jun 12, 2026·3 sources
00
Jun 11, 2026

Listeria Outbreak Linked to Clover Hill Dairy Cheese Kills One, Sickens 12 Across Four States

A multistate Listeria outbreak traced to requesón and soft ricotta-style cheeses from Clover Hill Dairy has resulted in one death in Maryland and 12 confirmed illnesses across Illinois, Maryland, New York, and Virginia. At least 10 people have been hospitalized as federal and state health officials continue their investigation.

Jun 11, 2026·5 sources
00
Jun 9, 2026

FDA approves bemotrizinol, first new sunscreen ingredient in over 25 years

The U.S. Food and Drug Administration on Tuesday approved bemotrizinol as a permitted active ingredient for over-the-counter sunscreens, marking the first new UV filter cleared since the late 1990s. The broad-spectrum ingredient has been widely used in Europe and Asia for years.

Jun 9, 2026·5 sources
00

GSK Acquires Nuvalent for $10.6 Billion to Expand Cancer Drug Portfolio

UK pharmaceutical giant GSK has entered an agreement to acquire U.S.-based cancer drugmaker Nuvalent for $10.6 billion, adding targeted cancer therapies to its portfolio in one of the year's largest biopharma acquisitions.

Jun 9, 2026·3 sources
00

First human receives cellular reprogramming therapy in landmark anti-aging clinical trial

The first participant has been treated in a groundbreaking clinical trial testing cellular reprogramming technology designed to rejuvenate aging cells. This marks the first time such reverse-aging therapy has been administered to a human.

Jun 9, 2026·2 sources
00
Jun 8, 2026

Roche enters licensing deal with Nurix Therapeutics for blood cancer drug worth up to $2.3-3 billion

Swiss pharmaceutical giant Roche has signed an exclusive licensing and collaboration agreement with Nurix Therapeutics for bexobrutinib, a protein degrader drug targeting B cell malignancies and blood cancers. The deal value is reported as up to $2.3 billion by one source and up to $3 billion by another.

Jun 8, 2026·2 sources
00

AstraZeneca's experimental obesity pill achieves 10.5% weight loss in phase II trial

AstraZeneca announced results from a phase II trial showing its oral GLP-1 therapy reduced body weight by 10.5%, positioning the company to compete with Eli Lilly in the race to develop convenient pill-based obesity treatments. The drug is advancing to late-stage trials.

Jun 8, 2026·2 sources
00
Jun 5, 2026

FDA Launches Safety Study of Abortion Pill Mifepristone

The Food and Drug Administration has initiated a safety study of mifepristone, the abortion pill approved decades ago, as opponents push for new restrictions. The FDA's website currently states the drug is safe to use as indicated.

Jun 5, 2026·1 source
00
Jun 4, 2026

ADC Therapeutics Blood Cancer Drug Trial Shows More Deaths Despite Meeting Primary Endpoint

ADC Therapeutics shares plunged 53% in premarket trading after a late-stage study of its blood cancer drug showed more deaths among treated patients, despite meeting its main goal. The safety signal represents a significant setback for the company's development program.

Jun 4, 2026·1 source
00
Jun 3, 2026

GLP-1 Drugs Show Beneficial Effects Across Multiple Cancer Types, New Research Suggests

Research indicates that GLP-1 drugs may have beneficial effects across many types of cancer, expanding the potential therapeutic applications of this drug class beyond diabetes and obesity.

Jun 3, 2026·1 source
00
Jun 2, 2026

FDA Declines Approval of Cingulate's ADHD Treatment Over Manufacturing Concerns

The U.S. Food and Drug Administration rejected Cingulate's drug for attention deficit hyperactivity disorder, citing manufacturing-related issues that need to be resolved before approval can be granted.

Jun 2, 2026·1 source
00

Abivax Shares Plunge Over 30% as Cancer Cases Overshadow Inflammatory Bowel Disease Trial Results

French biotech Abivax saw its stock tumble over 30% after reporting late-stage trial data for its ulcerative colitis drug, with investors focusing on safety concerns related to cancer cases despite the treatment showing efficacy.

Jun 2, 2026·2 sources
00
Jun 1, 2026

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.

Jun 1, 2026·4 sources
00
May 31, 2026

Experimental drug daraxonrasib nearly doubles survival time for pancreatic cancer patients in clinical trial

Clinical trial results show that daraxonrasib, an experimental daily pill, nearly doubled overall survival rates for patients with advanced pancreatic cancer compared to traditional chemotherapy. Medical experts are calling the results a 'game changer' for treating one of the deadliest forms of cancer.

May 31, 2026·8 sources
00

Akeso and Summit's Lung Cancer Drug Extends Survival by 34% in Late-Stage China Trial

Ivonescimab, an experimental drug combining two immunotherapy mechanisms, reduced the risk of death by 34% compared to standard immunotherapy in patients with advanced squamous non-small cell lung cancer in a closely watched Chinese trial. The drug helped patients live 15% longer than BeOne Medicines' Tevimbra.

May 31, 2026·3 sources
00

Johnson & Johnson's Prostate Cancer Drug Reduces Risk of Cancer Spread and Death in Late-Stage Study

J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.

May 31, 2026·2 sources
00

Novartis Experimental Radiopharma Drug Shows Anti-Tumor Activity in Early Prostate Cancer Study

Novartis reported early data showing its experimental actinium-based radiopharma drug demonstrated anti-tumor activity against prostate cancer, including in patients previously treated with its older therapies.

May 31, 2026·1 source
00
May 30, 2026

Mineralys Therapeutics' Experimental Drug Significantly Reduces Blood Pressure in Chronic Kidney Disease Patients

Mineralys Therapeutics presented new data at a major European medical conference showing their experimental pill significantly reduced blood pressure in patients with chronic kidney disease.

May 30, 2026·1 source
00

Incyte Blood Cancer Drug Combo Reduces Disease Progression Risk in Aggressive Lymphoma

Incyte's Monjuvi as part of a multi-drug regimen for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death, though with a high side-effect rate.

May 30, 2026·1 source
00

Radioactive Brain Implant Reduces Tumor Recurrence and Boosts Survival After Cancer Surgery

Scientists found that using a radioactive implant precisely where a brain tumor was removed cuts tumor recurrence and improves survival for patients with brain metastases.

May 30, 2026·1 source
00

DNA Test Could Allow Millions of Breast Cancer Patients to Safely Avoid Chemotherapy

Scientists have developed a DNA test that can distinguish between breast cancer patients who are likely to benefit from chemotherapy and those who can safely avoid it, potentially sparing millions from unnecessary treatment.

May 30, 2026·1 source
00
May 29, 2026

FDA Approves MannKind's Inhaled Insulin for Children with Diabetes

The FDA approved expanded use of MannKind's inhaled rapid-acting insulin for children under 18 with diabetes, offering pediatric patients a needle-free treatment option for the first time.

May 29, 2026·1 source
00

Bristol Myers Squibb's Mezigdomide Delays Disease Progression in Late-Stage Multiple Myeloma Trial

Bristol Myers Squibb announced its experimental oral drug mezigdomide successfully delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to prior treatments.

May 29, 2026·1 source
00

Agios Pharmaceuticals Discontinues Blood Cancer Drug Program After Mid-Stage Trial Failure

Agios Pharmaceuticals announced it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show sufficient benefit, marking a setback for the rare disease program.

May 29, 2026·1 source
00
May 28, 2026

GSK's Experimental Hepatitis B Drug Achieves Functional Cure in Nearly 1 in 5 Patients in Late-Stage Trials

GSK reported that its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, vastly outpacing current treatments and raising hopes for a finite treatment course as an alternative to lifelong therapy.

May 28, 2026·2 sources
00
May 27, 2026

Apogee Therapeutics Secures Up to $1.3 Billion from Blackstone for Eczema Drug Development

Apogee Therapeutics announced a financing deal with Blackstone Life Sciences worth up to $1.3 billion to support late-stage development and potential commercialization of its experimental eczema drug.

May 27, 2026·1 source
00
May 25, 2026

Eli Lilly's Gene-Editing Therapy Reduces Cholesterol by 62% in Early Clinical Trial

Eli Lilly reported that a high dose of its gene-editing therapy from Verve Therapeutics reduced cholesterol levels by 62% in participants in an early-stage clinical trial, representing a significant advance in gene-editing treatments for cardiovascular disease.

May 25, 2026·1 source
00
May 22, 2026

Big Tobacco Donated $5 Million to MAGA Inc. Before FDA Vape Policy Change

Reynolds American disclosed a $5 million contribution to MAGA Inc. approximately one week before the FDA issued new guidance on flavored vapes, raising questions about potential influence on regulatory policy.

May 22, 2026·1 source
00
May 21, 2026

Eli Lilly's Retatrutide Achieves Up to 30% Weight Loss in Phase 3 TRIUMPH-1 Trial

Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial showing retatrutide, an experimental triple-agonist obesity drug, achieved average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks on the highest dose, matching weight reduction levels typically seen with bariatric surgery.

May 21, 2026·3 sources
00
May 20, 2026

Kennedy Names Interim Surgeon General Amid HHS Leadership Vacancies

Stephanie Haridopolos, a family medicine physician and senior HHS adviser, will take on the surgeon general's duties on an interim basis as vacancies persist across the health department's leadership.

May 20, 2026·1 source
00
May 16, 2026

AstraZeneca's Imfinzi-Enfortumab Vedotin Combination Shows Historic Survival Gains in Bladder Cancer Trial

AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.

May 16, 2026·1 source
00
May 14, 2026

CDC Plans to Transfer 160+ Macaques to Nonprofit Sanctuary as Part of Animal Testing Reduction

The Centers for Disease Control and Prevention announced plans to transfer more than 160 macaques to Born Free USA's primate sanctuary in Texas as the agency seeks to phase out animal testing.

May 14, 2026·1 source
00

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source
00

CREATE Medicines Raises $122 Million for CAR-T Therapy Development

CREATE Medicines secured $122 million in funding to advance its CAR-T therapy candidates through human trials, alongside a company rebrand and expanded pipeline.

May 14, 2026·1 source
00

Regenxbio's Duchenne Gene Therapy Succeeds in Clinical Trial, Paving Way for FDA Submission

Regenxbio announced its experimental gene therapy for Duchenne muscular dystrophy succeeded in a clinical trial, enabling the company to move forward with an FDA submission.

May 14, 2026·1 source
00
May 13, 2026

Scientists Link Boy's Tumor to Gene Therapy Viruses in Rare Safety Finding

Doctors have directly linked a pediatric patient's tumor to gene therapy treatment viruses, marking a rare documented case of this safety risk. The finding comes as the gene therapy field grapples with safety-efficacy tradeoffs, with separate research showing that drugs designed to improve gene therapy safety may reduce effectiveness.

May 13, 2026·2 sources
00

FDA Reverses Course on Flavored Vapes, Allowing Products Without Authorization to Remain on Market

The FDA has implemented a new policy that will permit some flavored vaping products to stay on the market without agency authorization, raising concerns among public health experts after the agency previously warned about harmful kratom-derived products.

May 13, 2026·2 sources
00
May 12, 2026

FDA Commissioner Marty Makary Resigns After Tumultuous Tenure

FDA Commissioner Marty Makary is departing from his role amid ongoing turmoil at the agency. Jim Diamantas, the agency's top food official, is stepping in as Makary exits after months of controversy.

May 12, 2026·2 sources
00
May 10, 2026

China's NHWD-870 Receives Breakthrough Therapy Designation for Rare NUT Carcinoma

Chinese innovative drug NHWD-870 has received Breakthrough Therapy Designation for NUT carcinoma, a rare and aggressive cancer that has historically had very poor outcomes. The designation represents a significant milestone for patients with this previously untreatable condition.

May 10, 2026·1 source
00
May 9, 2026

Capricor Therapeutics Accuses Nippon Shinyaku of Mishandling Duchenne Drug Rollout

Capricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment, alleging the company is slow-walking commercialization plans.

May 9, 2026·1 source
00

Trump Administration Reportedly Plans to Fire FDA Commissioner Marty Makary

FDA Commissioner Marty Makary is reportedly facing ouster from the Trump administration, which would create another high-profile vacancy atop the Department of Health and Human Services under RFK Jr.

May 9, 2026·1 source
00
May 8, 2026

Six Former FDA Officials Describe Mass Exodus Following Trump Administration Cuts

Six former FDA officials shared their reasons for leaving the agency following significant staffing cuts and policy changes under the Trump administration. The departures come amid concerns about the agency's capacity to respond to public health threats like the ongoing hantavirus outbreak.

May 8, 2026·2 sources
00

Study Finds Fraudulent Citations Increasingly Common in Medical Research Papers

A new study reveals that fabricated citations that do not reference real academic papers are spreading in medical literature, with researchers attributing the problem partly to AI hallucinations. The trend is polluting the scientific record.

May 8, 2026·3 sources
00

AI Model Detects Pancreatic Cancer Up to 3 Years Earlier Than Doctors in Early Test

A new AI tool successfully identified early signs of pancreatic cancer in CT scans that human doctors would miss, potentially enabling detection up to three years before conventional diagnosis in initial testing.

May 8, 2026·1 source
00
May 7, 2026

Entrada Therapeutics' Next-Generation Duchenne Muscular Dystrophy Drug Fails Early Study

Entrada Therapeutics' next-generation therapy for Duchenne muscular dystrophy fell short in an early clinical study, representing a setback as multiple companies race to develop improved treatments for the genetic muscle-wasting disease.

May 7, 2026·1 source
00

FDA to Reconsider Ebvallo Treatment for Rare Cancer After Surprise Rejection

The FDA has reached an agreement with the developers of Ebvallo to reconsider the rare cancer treatment after its unexpected rejection, addressing the agency's main concerns.

May 7, 2026·1 source
00

Sanofi Withdraws Diabetes Drug from FDA's Expedited Review Program After Political Interference

Sanofi requested the FDA remove its type 1 diabetes drug from Commissioner Marty Makary's new speedy drug review voucher program after a political appointee interfered with the review process.

May 7, 2026·1 source
00
May 6, 2026

Duke University Develops Gene Therapy to Help Hearts Heal After Heart Attacks

Researchers at Duke University are developing a gene therapy treatment designed to help repair heart damage following heart attacks, potentially changing how doctors treat cardiac injury from the leading cause of death in the U.S.

May 6, 2026·1 source
00
May 5, 2026

Study finds single dose of psilocybin causes measurable brain changes in first-time users

Research published in Nature Communications shows that a 25mg dose of psilocybin induced both acute functional changes (detected via EEG one hour later) and enduring anatomical changes (detected via DTI one month later) in 28 healthy adults experiencing their first psychedelic trip.

May 5, 2026·3 sources
00

Cleveland Clinic, RIKEN, and IBM Simulate Largest Protein Using Quantum Computing

Cleveland Clinic, Japan's RIKEN research institute, and IBM achieved a breakthrough by simulating the largest protein to date using quantum computing technology, marking a significant advance in computational biology.

May 5, 2026·1 source
00

Cytokinetics' Heart Disease Drug Myqorzo Meets Primary Endpoints in Phase 3 Trial for Genetic Heart Condition

Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.

May 5, 2026·1 source
00

Johnson & Johnson's IBD Therapy Fails to Meet Primary Endpoint in Clinical Trial

Johnson & Johnson's closely watched inflammatory bowel disease therapy failed to show statistically significant improvement in patients during clinical trials, representing a setback for the pharmaceutical giant's gastroenterology pipeline.

May 5, 2026·1 source
00

UCB Acquires Maker of Antibody Treatments for Autoimmune Diseases

Belgian pharmaceutical company UCB has announced the acquisition of a company specializing in antibody treatments for autoimmune diseases, expanding its immunology portfolio.

May 5, 2026·1 source
00
May 4, 2026

State Health Insurance Marketplaces Shared Citizenship and Race Data with Ad Tech Companies

A Bloomberg investigation revealed that state health insurance marketplaces, including those in Virginia and Washington, D.C., shared users' personal information including citizenship and race data with advertisers through embedded ad trackers. Virginia and D.C. paused the data collection and sharing following the report.

May 4, 2026·2 sources
00

Latus Bio Raises $42 Million to Advance Huntington's Disease Gene Therapy Trial

Latus Bio secured $42 million in funding as it prepares to seek FDA approval to begin a clinical trial for its gene therapy targeting Huntington's disease, a progressive neurodegenerative disorder.

May 4, 2026·1 source
00

FDA Rejects Promising Melanoma Drug RP1 Twice, Raising Concerns About Drug Approval Process

The FDA has rejected RP1, a breakthrough melanoma treatment, twice despite its promise in treating skin cancer. The rejections have left medical professionals puzzled and concerned about implications for future drug approvals.

May 4, 2026·1 source
00
May 3, 2026

Microchip Nanoparticle Test Detects Pancreatic Cancer in Blood, Outperforming Biopsy in Early Trial

Scientists at Oregon Health & Science University developed a new technique using electronic jolts and nanoparticles to detect pancreatic cancer from blood samples, showing promise in early trials for earlier detection of this deadly cancer.

May 3, 2026·1 source
00

Stopping and Restarting GLP-1 Weight Loss Drugs May Reduce Their Effectiveness

Preclinical study from University of Pennsylvania researchers finds that inconsistent use of GLP-1 medications like Ozempic and Wegovy may significantly lessen their effectiveness for weight loss.

May 3, 2026·1 source
00

FDA Recalls Ghirardelli Powdered Beverages Over Salmonella Contamination Risk

The FDA has issued a recall for several Ghirardelli Chocolate Company powdered beverage mixes due to potential Salmonella contamination concerns.

May 3, 2026·1 source
00

Experimental KRAS G12D Cancer Drug Shows Tumor Shrinkage in First-in-Human Trial

Setidegrasib, an investigational targeted therapy drug, demonstrated ability to slow cancer growth and shrink tumors in a first-in-human clinical trial published in the New England Journal of Medicine, targeting a previously difficult-to-treat cancer mutation.

May 3, 2026·1 source
00
May 2, 2026

FDA Approves Merck's Idvynso, New Once-Daily Two-Drug HIV Treatment Tablet

The FDA has approved Merck's Idvynso (doravirine/islatravir), a once-daily, two-drug single tablet for treating HIV-1 infection in adults to replace current antiretroviral regimens in virologically suppressed patients.

May 2, 2026·1 source
00

Cigna to Exit ACA Individual Insurance Markets in 2027

Cigna announced it will exit Affordable Care Act individual insurance markets next year, adding to market instability after Congress failed to extend enhanced subsidies that helped people afford coverage. ACA membership is declining significantly.

May 2, 2026·1 source
00
May 1, 2026

Axsome Wins FDA Approval for Alzheimer's Agitation Treatment

The FDA has approved Axsome's drug for treating agitation in Alzheimer's disease patients, marking a new therapeutic option for this challenging symptom.

May 1, 2026·1 source
00

Trump withdraws Casey Means' surgeon general nomination, names Nicole Saphier as replacement

President Donald Trump announced Thursday he is nominating Dr. Nicole Saphier, a radiologist and former Fox News contributor, for surgeon general after Dr. Casey Means' nomination stalled in the Senate over concerns about her experience and vaccine stance.

May 1, 2026·5 sources
00

UK researchers develop tool to identify people at highest risk of obesity-related diseases

British researchers have created a new diagnostic tool designed to identify individuals most at risk of developing obesity-related diseases, which could help target weight-loss medications to those who would benefit most from treatment.

May 1, 2026·1 source
00

FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding List

FDA announced plans to exclude semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.

May 1, 2026·1 source
00
Apr 30, 2026

Accelerated Brain Stimulation Shows Promise for Autism Communication in Five-Day Treatment

New research published in The Lancet shows that accelerated continuous theta burst stimulation (a-cTBS), a non-invasive brain stimulation technique, improved social communication in autistic children at one-month follow-up after just five days of treatment.

Apr 30, 2026·2 sources
00

Partial Meniscectomy Knee Surgery Shows No Benefit and May Be Harmful in 10-Year Follow-Up Study

A 10-year follow-up of the FIDELITY placebo-surgery controlled trial published in the New England Journal of Medicine reveals that partial meniscectomy, one of the world's most common knee surgeries, does not improve patient symptoms or function.

Apr 30, 2026·1 source
00

Mayo Clinic AI Model Detects Pancreatic Cancer Up to Three Years Before Diagnosis

Mayo Clinic's AI-assisted test model (REDMOD) can detect pancreatic ductal adenocarcinoma at stage 0, identifying subtle tissue changes up to three years before conventional diagnosis, validated in a landmark study.

Apr 30, 2026·3 sources
00
Apr 29, 2026

FDA Samples 312 Infant Formula Brands, Finds Low Levels of Heavy Metals and Contaminants

FDA testing of 312 major infant formula brands found low or undetectable levels of pesticide residue, PFAS, heavy metals and phthalates, providing reassurance about formula safety.

Apr 29, 2026·1 source
00

Seasonal Flu Vaccines May Reduce Severity of H5N1 Bird Flu Infections in Humans

Research suggests that seasonal influenza vaccination could provide cross-protection against H5N1 avian influenza, potentially reducing severity if the virus causes human infections during a pandemic scenario.

Apr 29, 2026·1 source
00

Bariatric Surgery Shows Greater Long-Term Cardiovascular Benefits Than GLP-1 Weight-Loss Medications

Mayo Clinic study finds metabolic and bariatric surgery provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 medications in people with obesity, despite both treatments improving heart health.

Apr 29, 2026·1 source
00

Boehringer Ingelheim's Obesity Drug Shows 16.6% Weight Loss in Clinical Trial

Boehringer Ingelheim reported that its experimental obesity drug achieved 16.6% weight loss in clinical trials, marking another entrant in the competitive GLP-1 weight loss drug market.

Apr 29, 2026·1 source
00

FDA Launches Real-Time Clinical Trial Monitoring Initiative Using AI

The FDA announced a new program to monitor clinical trials in real-time using cloud-based systems and AI, allowing regulators to see trial endpoints as they occur rather than waiting for final results.

Apr 29, 2026·2 sources
00

Breakthrough Study Shows AI Can Predict Pancreatic Cancer Years in Advance

New study shows artificial intelligence can identify early signs of pancreatic cancer years before diagnosis, offering potential for earlier intervention and improved survival outcomes.

Apr 29, 2026·3 sources
00
Apr 28, 2026

CDC Issues Alert for Drug-Resistant Salmonella Outbreak Linked to Backyard Poultry Across 13 States

At least 34 people in 13 states have been infected with antibiotic-resistant salmonella traced to contact with backyard poultry, according to CDC warnings issued to the public.

Apr 28, 2026·1 source
00

Eli Lilly Partners with AI Startup Profluent to Develop Next-Generation Gene Editors Beyond CRISPR

Eli Lilly has entered a deal with AI startup Profluent to develop AI-designed enzymes capable of inserting entire genes, moving beyond traditional CRISPR technology. The partnership aims to reshape genetic medicine by using artificial intelligence to create novel gene editing tools.

Apr 28, 2026·1 source
00

Supreme Court Divided on Blocking Thousands of Roundup Cancer Lawsuits

The Supreme Court appeared divided during oral arguments over whether to block thousands of lawsuits alleging that Bayer's Roundup weedkiller failed to warn consumers it could cause cancer, a case with multibillion-dollar implications for the pharmaceutical industry.

Apr 28, 2026·1 source
00

Minimally Invasive Heart Procedure Outperforms Medication for Advanced Atrial Fibrillation in Major International Trial

A major international clinical trial found that a minimally invasive heart procedure may be a better first-line treatment than medication for people with advanced forms of atrial fibrillation, offering improved outcomes for patients with this common heart rhythm disorder.

Apr 28, 2026·1 source
00

High-Precision Radiation Therapy Reduces Life-Threatening Heart Arrhythmias by 80%

Two studies report that targeted, noninvasive radiation therapy (proton beam therapy) reduced episodes of life-threatening cardiac arrhythmias by nearly 80% in critically ill patients, representing the first large-scale and first-in-human evidence for this approach.

Apr 28, 2026·2 sources
00
Apr 27, 2026

Veradermics' Hair Loss Drug Succeeds in Late-Stage Clinical Trial

Veradermics reported positive results from a late-stage trial of its hair loss treatment, positioning the company as one of the most advanced players in the hair loss field amid surging investor interest.

Apr 27, 2026·1 source
00

Intellia Reports Positive Pivotal Trial Results for CRISPR-Based Treatment of Rare Swelling Disease

Intellia Therapeutics announced that its CRISPR-based gene editing treatment reduced swelling attacks in a pivotal trial for hereditary angioedema, a rare genetic disease. The results advance the CRISPR field's one-and-done treatment approach toward potential regulatory approval.

Apr 27, 2026·1 source
00
Apr 25, 2026

Continuous Glucose Monitors Significantly Improve Blood Sugar Control in Type 2 Diabetes Patients on Insulin

A major clinical trial found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin, offering evidence for expanded use of the technology beyond type 1 diabetes.

Apr 25, 2026·1 source
00
Apr 24, 2026

CMS and FDA Launch RAPID Coverage Pathway to Accelerate Medicare Access for Breakthrough Medical Devices

The Centers for Medicare & Medicaid Services and FDA announced a new pathway to streamline Medicare coverage for breakthrough medical devices, cutting red tape and providing predictability for device manufacturers and faster patient access to life-changing technologies.

Apr 24, 2026·2 sources
00

FDA Approves First Gene Therapy for Hereditary Hearing Loss

The FDA has greenlit a first-of-its-kind gene therapy to treat a rare form of hereditary hearing loss, marking a breakthrough that could pave the way for other hearing impairment treatments. Follow-up research confirms the therapy yields lasting hearing gains for patients with inherited deafness.

Apr 24, 2026·2 sources
00
Apr 23, 2026

Low-Dose Triple-Pill Combination Reduces Recurrent Stroke Risk by 40% in Global Trial

A global clinical trial found that GMRx2, a single pill combining three low-dose blood pressure medications, significantly reduced the risk of recurrent stroke in patients with intracerebral hemorrhage and high blood pressure by approximately 40%.

Apr 23, 2026·1 source
00
Apr 22, 2026

Gene Therapy for Inherited Deafness Shows Lasting Hearing Restoration Years After Treatment

International clinical trial results show that gene therapy for a rare form of genetic deafness successfully restored hearing in 90% of participants, with improvements lasting years after treatment. The study was co-led by Mass General Brigham and China's Eye & ENT Hospital of Fudan University.

Apr 22, 2026·2 sources
00

Roche Presents Multiple Sclerosis Drug Data Ahead of Regulatory Submission

Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.

Apr 22, 2026·1 source
00

Kyverna Therapeutics Plans FDA Submission for Stiff Person Syndrome Cell Therapy

Kyverna Therapeutics announced plans to submit its one-time CAR-T cell therapy for stiff person syndrome to the FDA after late-stage trial showed improvements in mobility and reduced disabilities in patients with the rare neurological disease.

Apr 22, 2026·1 source
00

Immunotherapy Shows Clinical Benefit in Advanced Colorectal Cancer as First-Line Treatment

Clinical trial results demonstrate that immunotherapy as first-line treatment provides clinical benefit for patients with advanced colorectal cancer, offering an alternative to chemotherapy for a disease increasingly affecting younger patients.

Apr 22, 2026·2 sources
00

Revolution Medicines Presents Additional Strong Data on KRAS-Targeting Pancreatic Cancer Drug

Revolution Medicines presented new positive clinical trial data at AACR for its KRAS-targeting drug in pancreatic cancer patients, building on previously reported breakthrough survival results and expanding evidence for a novel class of treatments beyond current KRAS inhibitors.

Apr 22, 2026·3 sources
00
Apr 21, 2026

BioAge Labs Reports Experimental Cardiovascular Drug Significantly Reduced Inflammation in Early Study

BioAge Labs announced its investigational pill for cardiovascular risk prevention significantly reduced inflammation markers in an early-stage clinical study, representing potential progress in heart disease prevention.

Apr 21, 2026·1 source
00

Blood Test Detects Aggressive Brain Tumors Early and Could Reduce Need for Risky Surgery

University of Sussex researchers, in collaboration with international scientists, identified a blood test capable of early diagnosis of the most aggressive form of brain cancer, potentially eliminating the need for dangerous surgical biopsies.

Apr 21, 2026·1 source
00

Breakthrough Prize Awards $3 Million Each to Six Scientists for Gene Therapies and KRAS Research

The 2026 Breakthrough Prize honored six laureates with $3 million awards for discoveries including gene therapies for inherited blindness and sickle cell disease, as well as groundbreaking work on KRAS cancer targets. Boston-area researchers were among those recognized.

Apr 21, 2026·2 sources
00

CAR-T Therapy Shows Promise in Preventing Multiple Myeloma in High-Risk Patients

Early trial results presented at AACR show CAR-T cell therapy may prevent smoldering multiple myeloma from progressing to active disease in high-risk patients, representing a potential preventive approach to cancer treatment.

Apr 21, 2026·2 sources
00

Frequent Daytime Napping Linked to Early Signs of Health Decline in Older Adults

Frequent, long, or early-day naps in older adults are linked to higher mortality risk and may signal underlying conditions like cardiovascular disease, neurodegeneration, or sleep disorders, suggesting daytime sleep patterns could serve as an early warning sign of declining health.

Apr 21, 2026·4 sources
00
Apr 20, 2026

Prenatal Medication Exposure Linked to Increased Autism Risk in Landmark Study

A large-scale study analyzing millions of US birth records has identified a significant association between prenatal prescription of certain common drugs and increased autism risk in children.

Apr 20, 2026·2 sources
00

FDA Approves At-Home Starting Dose for Eisai-Biogen Alzheimer's Drug

The U.S. Food and Drug Administration approved an at-home starting dose of Eisai and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver rather than requiring initial doses in a clinical setting.

Apr 20, 2026·2 sources
00

Teen Cannabis Use Linked to Slower Cognitive Development in Largest US Study

University of California San Diego researchers found that teenagers who begin using cannabis show slower gains in thinking and memory skills as they develop, according to a study published in Neuropsychology.

Apr 20, 2026·1 source
00

Common Plant Shows Promise for Removing Microplastics From Drinking Water

Extract from seeds of the moringa plant can effectively bind and remove microplastics from water, matching or even outperforming conventional chemical treatments, offering a low cost natural solution for cleaner drinking water, especially in small or resource limited communities.

Apr 20, 2026·3 sources
00

Brain Study Links Microplastics to Health Risks

Analysis of human brain tissue shows microplastics and nanoplastics are present in both tumor and healthy samples, confirming their ability to cross into the brain, though their concentrations, distribution, and direct health effects remain uncertain and require further study.

Apr 20, 2026·2 sources
00
Apr 19, 2026

Researchers Develop Method to Supercharge Cancer-Killing Immune Cells

Scientists found a way to make cancer-killing immune cells more powerful and precise by adding specific signaling components that boost the cells' readiness to attack tumors, offering a new approach to immunotherapy.

Apr 19, 2026·1 source
00

mRNA Cancer Vaccines Show Effectiveness Even Without Key Immune Cells in New Research

Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.

Apr 19, 2026·1 source
00

American College of Physicians Issues New Mammography Screening Guidelines for Women

New guidance recommends all average-risk women ages 50-74 receive biennial screening mammography for breast cancer, with individualized decision-making for women ages 40-49.

Apr 19, 2026·1 source
00

Breakthrough Prize Awards $3 Million to Researchers Behind First Sickle Cell CRISPR Therapy

Dr. Swee Lay Thein and Dr. Stuart Orkin received the $3 million Breakthrough Prize in Life Sciences for research that led to the development of the first CRISPR-based therapy for sickle cell disease.

Apr 19, 2026·1 source
00
Apr 18, 2026

Xanax Recalled Nationwide Over Failed Quality Specifications

A widely used anxiety medication (Xanax) is being pulled from shelves nationwide due to failed dissolution specifications, according to the FDA.

Apr 18, 2026·1 source
00

Folic Acid Supplementation Before Pregnancy Halves Birth Defect Risk in Women Taking Antiseizure Medication

Study finds women with epilepsy taking antiseizure medication who initiate high-dose folic acid before pregnancy have approximately 45% reduced risk of major congenital anomalies in their children.

Apr 18, 2026·1 source
00

Blood Pressure Drug Shows Effectiveness Against Antibiotic-Resistant Bacteria

Research published in Nature Communications reveals that a common blood pressure medication can effectively treat infections from antibiotic-resistant bacteria, offering a potential new weapon against drug-resistant infections responsible for over 35,000 U.S. deaths annually.

Apr 18, 2026·1 source
00
Apr 17, 2026

Roche Launches New Phase 3 Trial of Elevidys for European Approval

Roche is initiating another Phase 3 clinical trial of the controversial Duchenne muscular dystrophy gene therapy Elevidys, aiming for potential approval in European markets.

Apr 17, 2026·1 source
00

Optimism Linked to 15% Lower Dementia Risk in 14-Year Study

Harvard T.H. Chan School of Public Health researchers found that higher levels of optimism are associated with a 15% reduction in dementia risk over 14 years, independent of other known risk factors.

Apr 17, 2026·2 sources
00

First-in-Human Trial Shows Liver Transplant Patients Can Stop Immunosuppressants After Cell Therapy

UPMC and University of Pittsburgh researchers successfully weaned multiple liver transplant patients off all immunosuppressant drugs for over three years using a pre-transplant cell therapy approach, representing a potential breakthrough in organ transplantation.

Apr 17, 2026·2 sources
00

Buprenorphine Safe for Treating Opioid Addiction During Pregnancy, Study Finds

Children born to mothers who used buprenorphine for opioid addiction during pregnancy show no greater risk of neurodevelopmental disorders like ADHD and autism compared to children whose mothers did not use the medication, providing reassurance about this critical treatment option.

Apr 17, 2026·1 source
00

Datopotamab Deruxtecan Nearly Doubles Survival in Triple-Negative Breast Cancer Trial

Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.

Apr 17, 2026·1 source
00
Apr 16, 2026

FDA Petition Seeks to Revoke Approval of Roche's Ocrevus for Primary Progressive Multiple Sclerosis

The FDA is reviewing a petition to revoke approval of ocrelizumab (Ocrevus), Roche's top-selling drug, for treating primary progressive MS, raising questions about whether the drug may be causing more harm than good in this patient population.

Apr 16, 2026·1 source
00

FDA Requests Additional Liver Injury Data on Eli Lilly Obesity Pill Foundayo

The FDA has asked Eli Lilly for more data on liver injury linked to its newly approved obesity pill Foundayo.

Apr 16, 2026·1 source
00

New Anti-Clotting Drug Asundexian Reduces Stroke Risk Without Increased Bleeding

Large international trial found that investigational drug asundexian reduces stroke risk in people who recently experienced stroke or TIA without added bleeding complications.

Apr 16, 2026·1 source
00
Apr 15, 2026

Loneliness Associated with Higher Risk of Degenerative Heart Valve Disease

Adults who reported feeling lonely had a higher risk of developing degenerative heart valve disease, even after accounting for traditional heart disease risk factors and genetics, according to new research.

Apr 15, 2026·1 source
00

BRCA Gene Mutations Now Linked to Thyroid, Bladder, Skin and Head-Neck Cancers

International research led by RIKEN Center for Integrative Medical Sciences discovered new associations between pathogenic BRCA1 and BRCA2 gene variants and four additional cancer types beyond the previously known breast and ovarian cancers.

Apr 15, 2026·1 source
00

FDA Considers Easing Peptide Restrictions as RFK Jr. Voices Support

Federal regulators are reviewing potential changes to peptide restrictions as support from Robert F. Kennedy Jr. signals a possible shift toward broader access and evolving oversight of emerging therapies.

Apr 15, 2026·2 sources
00
Apr 14, 2026

Revolution Medicines Pancreatic Cancer Drug Doubles One-Year Survival in Clinical Trial

A new drug developed at Northwestern University showed patients with pancreatic cancer living twice as long as those on chemotherapy in a Phase III trial, with former Sen. Ben Sasse among participants.

Apr 14, 2026·3 sources
00

Radon Gas Exposure Linked to Increased Ovarian Cancer Risk

New research identifies radon, an invisible radioactive gas, as a risk factor for ovarian cancer in women, adding to known health hazards of the environmental contaminant.

Apr 14, 2026·1 source
00

Norway's 'Oslo Patient' Achieves HIV Remission After Stem Cell Transplant from Brother

A Norwegian man has been effectively cured of HIV after receiving a stem cell transplant from his brother, marking a rare case of HIV remission through transplantation.

Apr 14, 2026·1 source
00

FDA Pushes Drugmakers to Report Missing Clinical Trial Results

FDA officials revealed that nearly 30% of clinical trial studies highly likely to fall under mandatory reporting requirements failed to submit results, prompting new enforcement efforts to improve transparency.

Apr 14, 2026·1 source
00
Apr 13, 2026

Simple Procedure Relieves Post-Thrombotic Syndrome in Major Clinical Trial

A major multi-site clinical trial co-led by Washington University School of Medicine demonstrates that a procedure can relieve post-thrombotic syndrome, a common and painful complication following deep vein thrombosis.

Apr 13, 2026·1 source
00

Teen and Young Adult Cancer Survivors Face Double the Risk of Developing Later Cancers

Research published in the Canadian Medical Association Journal found that survivors of cancer during their teen and young adult years face twice the risk of developing most types of subsequent cancers compared to the general population.

Apr 13, 2026·1 source
00

Genetic Variants Explain Why GLP-1 Drugs Like Ozempic Don't Work for 10% of Patients

New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.

Apr 13, 2026·1 source
00

Allogene Therapeutics' Off-the-Shelf CAR-T Therapy Eliminates Residual Cancer in B-Cell Lymphoma Patients

Allogene Therapeutics reported new data showing its allogeneic (off-the-shelf) CAR-T treatment successfully eliminated residual cancer cells in B-cell lymphoma patients, potentially offering an easier-to-administer alternative that could delay or prevent cancer recurrence.

Apr 13, 2026·1 source
00

Injectable Therapy Shows Promise to Reverse Osteoarthritis Within Weeks

Research team from University of Colorado Boulder, CU Anschutz, and Colorado State University developed new therapies that prompt aging or damaged joints to regenerate, potentially reversing osteoarthritis in a matter of weeks.

Apr 13, 2026·1 source
00

Reversible Male Contraceptive Shows Promise in Temporarily Stopping Sperm Production

Cornell scientists achieved a major breakthrough in developing a reversible male contraceptive that can temporarily halt sperm production, representing a significant advance in male birth control options.

Apr 13, 2026·2 sources
00
Apr 12, 2026

Nerve Growth Factor Alone Triggers Osteoarthritis-Like Changes in Healthy Mice

Research demonstrates that nerve growth factor (NGF), a protein critical for nerve development, can independently cause osteoarthritis-like joint changes in healthy mice without other injury.

Apr 12, 2026·1 source
00

Researchers Discover Chloride Channel PACC1 as New Target for Sepsis Treatment

Scientists have identified a previously unknown immune mechanism where the chloride channel PACC1 plays a crucial role in helping immune cells kill bacteria, offering a potential new therapeutic target for sepsis.

Apr 12, 2026·1 source
00

Two-Antibody Cocktail Developed to Combat Drug-Resistant RSV

Chinese scientists have developed a two-antibody cocktail for respiratory syncytial virus that prevented drug resistance in laboratory studies, addressing a persistent problem in RSV treatment.

Apr 12, 2026·1 source
00

New Anemia in Adults Identified as Early Warning Sign of Cancer Risk

Population-based study from Karolinska Institutet published in BMJ Oncology finds that newly detected anemia in adults is associated with increased cancer risk and higher mortality rates.

Apr 12, 2026·1 source
00

California Study Links Flavored Tobacco Bans to Reduced Youth Vaping

University of California San Diego research finds that local sales bans on flavored tobacco products in California are associated with decreased youth vaping rates over time without increasing cigarette use.

Apr 12, 2026·1 source
00
Apr 11, 2026

Experimental Parkinson's Drug Reduces Disease-Linked Protein by Up to 60% in First Human Trial

An experimental drug designed to silence a gene strongly linked to Parkinson's disease showed encouraging effects in reducing the target protein by up to 60% in a first-in-human clinical trial published in Nature Medicine.

Apr 11, 2026·1 source
00

COVID-19 Spike Protein Linked to Increased Lung Cancer Risk Through Inflammatory Pathway

New study suggests SARS-CoV-2 may slightly increase lung cancer risk by triggering a biological chain reaction driven by the virus's spike protein that promotes inflammation and tumor development.

Apr 11, 2026·1 source
00

Leukemia Cells Use Sugar-Coated Protein to Evade Immune System Detection

Researchers identified a key mechanism leukemia cells use to hide from the immune system, explaining why the cancer resists many modern immunotherapies.

Apr 11, 2026·1 source
00

CAR-T Therapy Shows Continued Success in Autoimmune Diseases Five Years After Lupus Breakthrough

Five years after initial lupus breakthrough, CAR-T cell therapy continues to demonstrate remissions in autoimmune diseases, generating significant research investment and experimentation beyond its original cancer applications.

Apr 11, 2026·1 source
00
Apr 10, 2026

FDA Rejects Replimune's Skin Cancer Drug for Second Time

The FDA has rejected Replimune's cancer drug candidate for the second time, a treatment that had become a flashpoint at the agency over approval standards.

Apr 10, 2026·1 source
00
Apr 9, 2026

Scientists Map Brain's Neural Connections Using RNA Barcodes in Major Breakthrough

Researchers developed a cutting-edge technique using RNA 'barcodes' to map how neurons connect, capturing thousands of synaptic links with single-synapse precision, transforming brain mapping capabilities.

Apr 9, 2026·1 source
00

Lab-Grown Pineal Gland Organoids Successfully Produce Melatonin

Yale School of Medicine researchers developed functional pineal gland organoids that produce melatonin, offering a new model for studying sleep disorders and circadian rhythm regulation.

Apr 9, 2026·1 source
00

AI Outperforms Doctors at Summarizing Cancer Pathology Reports in Northwestern Study

Northwestern Medicine study found AI models from Meta, Google, and DeepMind generate more complete summaries of complex cancer pathology reports than physicians, potentially improving clinical communication and patient understanding.

Apr 9, 2026·1 source
00

Study Links $35 Insulin Cap to Improved Treatment Adherence in Type 2 Diabetes

Research demonstrates that capping insulin costs at $35 per month significantly improves medication adherence among patients with type 2 diabetes, providing evidence for price control policies.

Apr 9, 2026·1 source
00

HRT Patches Treat Prostate Cancer as Effectively as Standard Injections with Fewer Side Effects

A large UK trial published in the New England Journal of Medicine found that women's hormone replacement therapy patches can treat prostate cancer just as effectively as standard hormone injections but with fewer severe side effects.

Apr 9, 2026·1 source
00

Gene-Edited Stem Cells Help Five Beta-Thalassemia Patients Stop Transfusions in Clinical Trial

A phase 1 clinical trial demonstrated that stem cell transplantation using gene-edited cells rapidly and effectively restored hemoglobin production in five patients with beta-thalassemia, allowing them to discontinue blood transfusions.

Apr 9, 2026·1 source
00
Apr 8, 2026

23andMe Identifies Genetic Variants Predicting GLP-1 Drug Response and Side Effects

Research from 23andMe found that changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs and whether they will experience nausea or vomiting.

Apr 8, 2026·1 source
00

Smart Contact Lens Monitors Eye Pressure and Delivers Glaucoma Drugs in Preclinical Tests

Researchers at the Terasaki Institute for Biomedical Innovation developed a smart contact lens that combines real-time intraocular pressure monitoring with responsive drug delivery for glaucoma patients, showing promise in preclinical models.

Apr 8, 2026·2 sources
00

Study Predicts 10% Rise in HIV Infections if CDC Testing Funds End

Research modeling shows that ending CDC funding for HIV testing to local health departments could lead to a 10% increase in HIV infections, highlighting the critical role of timely diagnosis and treatment in preventing transmission.

Apr 8, 2026·1 source
00

Virus from Seafood Jumps to Humans, Causing Chronic Eye Disease

A virus that typically infects marine animals such as shrimp and fish has jumped to humans and is causing chronic eye disease in some people, according to a study published in Nature Microbiology.

Apr 8, 2026·1 source
00

Federal Judge Refuses to Block Mifepristone Mail Distribution, Orders FDA Review

A federal judge declined to block filling prescriptions for the abortion pill mifepristone by mail across the U.S., but ordered the FDA to complete a review of the practice.

Apr 8, 2026·1 source
00
Apr 7, 2026

Gilead Acquires German Cancer Biotech Tubulis for Over $3 Billion

Gilead Sciences is acquiring German biotech company Tubulis for more than $3 billion in a deal that will expand its oncology pipeline with antibody-drug conjugate technology.

Apr 7, 2026·1 source
00

Study Finds Many Cancer Patients Not Receiving Genomic Tests That Could Guide Treatment

Research reveals a significant gap in cancer care, with many patients not receiving genomic testing that could improve their survival chances and guide personalized treatment decisions.

Apr 7, 2026·1 source
00

FDA Supports Proposals to Incentivize Domestic Drug Manufacturing

The FDA has backed proposals in the Trump administration's budget aimed at encouraging pharmaceutical companies to test and manufacture drugs domestically, including potential tariffs and incentives.

Apr 7, 2026·2 sources
00

St. Jude and Partners Develop Data Platform Unifying Blood Cancer Genomics and Clinical Data

Scientists at St. Jude Children's Research Hospital, the American Society for Hematology, and Munich Leukemia Laboratory created a data-sharing platform that unites genomics, gene expression, and clinical data for blood cancers.

Apr 7, 2026·1 source
00

Biosimilar drugs gain ground in US market with new approvals and market leadership

The FDA approved Ranluspec as the first interchangeable ranibizumab biosimilar, Biocon launched denosumab biosimilars Bosaya and Aukelso in the US, and Celltrion's Truxima became the first Korean biosimilar to lead its segment in US prescriptions.

Apr 7, 2026·3 sources
00
Apr 6, 2026

Mayo Clinic Develops Method to Identify Immune-Triggering Proteins in Transplants

Mayo Clinic researchers have developed a new method to identify which proteins are most likely to trigger an immune response, a discovery that could help improve transplant care and regenerative medicine outcomes.

Apr 6, 2026·1 source
00

Scripps Research Develops New Anti-Inflammatory Drug Class That Preserves Immune Function

Scripps Research scientists have developed a first-in-class drug compound that reduces harmful inflammation while leaving the body's ability to fight infections intact, addressing a long-sought goal in treating autoimmune diseases.

Apr 6, 2026·1 source
00

UCLA Researchers Develop Blood Test to Detect Multiple Cancers and Diseases Simultaneously

Scientists at UCLA have developed a simple and cost-effective blood test that shows promise in early studies for detecting multiple cancers, various liver conditions, and organ abnormalities from a single blood sample.

Apr 6, 2026·1 source
00

Antidepressant Shows Promise in Reducing Methamphetamine Use

A new study demonstrates that a common antidepressant helps people cut back on methamphetamine use, offering potential treatment option for highly addictive stimulant.

Apr 6, 2026·1 source
00

Over 3 Million Eye Drops Recalled Over Sterility Concerns

More than 3 million bottles of over-the-counter eye drops are being recalled after officials raised concerns about the product's safety and sterility.

Apr 6, 2026·1 source
00

FDA Delay Forces Small Biotech Company to Shut Down Operations

A small biotech company was forced to wind down operations after the FDA abruptly postponed a key meeting for four months, despite reaching a clinical trial agreement in February that came too late.

Apr 6, 2026·2 sources
00
Apr 5, 2026

Study Links Irregular Bedtime in Midlife to Doubled Risk of Cardiovascular Disease

Research from the University of Oulu suggests that large variations in bedtime during midlife may double the risk of cardiovascular events, highlighting the importance of consistent sleep schedules for heart health.

Apr 5, 2026·1 source
00

University of Tartu Identifies MGRN1 Gene Variant Linked to Fetal Heart Malformations

Researchers at the University of Tartu Faculty of Medicine have identified a rare variant in the MGRN1 gene that may cause congenital heart malformations in fetuses, a gene not previously associated with cardiac defects.

Apr 5, 2026·1 source
00

Abu Dhabi Stem Cells Center Develops Technique to Generate Brain Stem Cells from Patient's Own Cells

Abu Dhabi Stem Cells Center has achieved a breakthrough in regenerative medicine by developing a technique that allows scientists to generate brain stem cells using a patient's own cells, advancing personalized medicine approaches.

Apr 5, 2026·1 source
00
Apr 4, 2026

Transcranial Magnetic Stimulation Shows Promise for PTSD Treatment by Targeting Brain's Fear Center

Research from Emory University and University of Iowa demonstrates that noninvasive transcranial magnetic stimulation (TMS) can calm the brain's fear center and significantly reduce PTSD symptoms, offering a non-surgical, non-medication treatment option.

Apr 4, 2026·2 sources
00

Small Molecule Drug Candidate Shows Promise for Rare Kidney Stone Disease with No Current Treatment

Scientists at the Buck Institute for Research on Aging demonstrated that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones in preclinical studies.

Apr 4, 2026·1 source
00

World's Largest Study Confirms Most Penicillin Allergy Labels Are Incorrect

Melbourne researchers led the world's largest study confirming that most patients labeled as allergic to penicillin are not truly allergic, with lead researchers calling it a 'game changer' for antibiotic prescribing practices.

Apr 4, 2026·1 source
00
Apr 3, 2026

Influenza Vaccine Reduces Heart Attack and Stroke Risk Even After Breakthrough Infection

New research shows that influenza vaccination significantly reduces the risk of heart attack and stroke even among people who contract the flu after vaccination, demonstrating cardiovascular benefits beyond infection prevention.

Apr 3, 2026·2 sources
00

Nigeria Unveils 400,000-Sample Biobank for Disease Research

The Nigerian Institute of Medical Research has unveiled a biobank housing over 400,000 biological samples, representing a major infrastructure development for disease research in Africa.

Apr 3, 2026·1 source
00
Apr 2, 2026

FDA Approves Eli Lilly's Obesity Pill, Setting Up Competition with Novo Nordisk

The FDA has approved Eli Lilly's oral obesity medication, marking a significant development in the weight-loss drug market and positioning it for direct competition against Novo Nordisk's Wegovy pill.

Apr 2, 2026·1 source
00
Apr 1, 2026

Plastic Additives Linked to 1.97 Million Preterm Births Worldwide in 2018

New analysis finds that exposure to chemicals used to make plastic more flexible may have contributed to approximately 1.97 million preterm births in 2018 alone, representing more than 8% of the world's total preterm births that year.

Apr 1, 2026·2 sources
00
Mar 31, 2026

Eli Lilly Acquires Centessa Pharmaceuticals for $6.3 Billion to Gain Narcolepsy Drug

Eli Lilly announced the acquisition of Centessa Pharmaceuticals in a deal worth at least $6.3 billion, gaining access to a promising narcolepsy treatment as part of its expansion strategy.

Mar 31, 2026·1 source
00

Kimchi Linked to Reduced Microplastics in New Study

New research suggests a widely consumed food may help remove harmful microplastics from the body by binding to particles or aiding their excretion, pointing to a potential dietary approach to reducing long-term exposure and related health risks.

Mar 31, 2026·3 sources
00
Mar 28, 2026

Birmingham, Alabama Residents Discover Water Supply Lacked Fluoride for Years Without Public Notice

Birmingham's water utility revealed that previous leadership had stopped fluoridating drinking water at three of its four treatment plants without informing the public, and is now making the cessation permanent.

Mar 28, 2026·1 source
00
Mar 27, 2026

Agent Orange Linked to MDS Blood Cancer in New Study Decades After Vietnam War

New research has established a connection between Agent Orange exposure during the Vietnam War and myelodysplastic syndrome (MDS) blood cancers, potentially enabling affected veterans to access benefits and treatment.

Mar 27, 2026·1 source
00
Mar 26, 2026

FDA Approves Rocket Pharmaceuticals Gene Therapy for Rare Immune Disorder

The FDA approved Kresladi, Rocket Pharmaceuticals' gene therapy for a rare immune disorder, despite testing in only nine patients. The approval represents a notable decision as the agency has recently taken tougher stances on rare disease drugs.

Mar 26, 2026·3 sources
00
Mar 25, 2026

FDA Approves Johnson & Johnson's Icotyde for Moderate-to-Severe Plaque Psoriasis

The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults.

Mar 25, 2026·1 source
00

FDA Approves Denali Therapeutics Drug for Hunter Syndrome

The FDA approved a new medicine from Denali Therapeutics for Hunter syndrome, a rare genetic disorder. The approval is notable following a recent string of FDA rejections for rare disease drugs.

Mar 25, 2026·1 source
00
Mar 24, 2026

FTC Reaches Settlement with CVS Over PBM Insulin Price Manipulation

The Federal Trade Commission struck a proposed settlement with CVS over charges that its pharmacy benefit manager manipulated insulin prices and impeded patient access. The FTC estimates the settlement will save Americans up to $7 billion in out-of-pocket costs over 10 years.

Mar 24, 2026·1 source
00
Mar 13, 2026

Harvard Study Finds IRA Drug Reforms Helping Medicare Patients Stay on Medications

A Harvard-backed study found that the Inflation Reduction Act's drug provisions are helping Medicare beneficiaries stay on their medications. However, the reforms have not yet reduced overall healthcare costs or financial anxiety for beneficiaries.

Mar 13, 2026·2 sources
00
Feb 26, 2026

Microplastics Found in Prostate Tumor Tissue

Study finds microplastics present in prostate tumor tissue, raising new questions about environmental exposure and potential links to cancer development.

Feb 26, 2026·4 sources
00
Dec 3, 2025

AI Systems Advance Treatment and Care for Blood Cancer Patients

Researchers have developed artificial intelligence tools to support clinical decision-making in hematologic malignancies, including HemaGuide from German Cancer Research Center for treatment recommendations and AI applications in palliative oncology for symptom management and prognostication.

Dec 3, 2025·2 sources
00

Top claims

  • ▪Prescribing warnings for Hibsago include risks of deteriorating kidney function, serious inflammatory adverse reactions such as vasculitis, and complications from improper injection
  • ▪Patients using Hibsago require regular blood tests during therapy to monitor for hepatic flares, reduced platelet counts, and kidney function risks
  • ▪Hibsago has secured regulatory approval in Japan and is under regulatory review by health authorities in China and Europe

People involved

Donald TrumpSusie WilesWilliam RutoCatherine L'EstrangeRobert F. Kennedy Jr.Casey Means

Subtopics

Drug Policy, Pricing & Approval524Pharma121Clinical trials115Cancer & Oncology74Clinical Trial Design & Evaluation65Clinical evaluation53Lifestyle, Wellness and Nutrition39Public healthcare38FDA drug approval37Infectious Disease and Outbreaks35Cancer treatment30Cancer Treatment & Therapies30Cancer treatment breakthroughs30Cancer Types30Drug development26Gene therapy26Mental Health & Wellbeing25Weight loss medications & GLP-1 drugs23GLP-1 medications22Longevity & biohacking22Pharmaceutical Industry20Government and Regulatory Policy19FDA drug approval process18GLP-1 / Weight-Loss Medications18

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories